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1.1 Tetraether lipids 
Archaea is the third domain of life; its members are distinguished from Eukarya and Bacteria 
by their unique structure and composition characteristics. (1). Therefore the members of 
Archaea survive in extreme habitats with acidic pH, high temperatures, low pressure or 
















This study focuses on two species of the Archea domain, namely Sulfolobus acidocaldarius 
and Thermoplasma acidophilum. The tetraether lipids used in this study were extracted form 
both of these species. Sulfolobus acidocaldarius is a hyper-thermophilic archaeon from the 
family Sulfolobaceae with optimum living conditions of about 80° C and pH 3 which makes 
them thermophiles and acidophiles respectively (2). Thermoplasma acidophilum is a 
thermoacidophilic archaebacterium which has optimal growth conditions at 59° C - 100° C 
and in acidic environments at pH 1-2. Thermoplasma acidophilum was isolated from a coal 
refuse pile by Darland et al. in 1970 (3).  
The ability of these organisms to survive in extreme environments is based on their specific 
lipid structure, which is highly distinctive from bacterial lipids, e.g. (i) the hydrocarbon ―tails‖ 
are linked to the glycerol backbone with an ether linkage instead of an ester linkage, (ii) these 
tails are attached to each other (iii) the carbon bonds are saturated with methyl groups (4) 
(Figure 2, 3). In the membrane of Archaea more than 15 different ether lipid structures are 
present (5). In this ether linkage, sn-2,3 configurations of the saturated phytanyl chains are 
attached to a glycerol backbone. This linkage is a sn-1,2 configuration in conventional ester 
lipids (1). 
The core lipid consists of 5-carbon repeating units that are bound together to form saturated 
isporanoid chains. These units are attached via ether bonds in sn-2,3 carbon positions to the 
glycerol backbone (6). The archaeol (standard ether, 2,3-di-O-phytanyl-sn-glycerol) with 
C20,20 is most common and dominant in Archaea and found in extreme halophiles (1). The tail 
to tail condensation of two archaeol moieties reveals caldarchaeols with C40,40 (standard 







Caldarchaeol is not found in extreme halophiles, but 0 to 65 % of methanogens and up to  
90 % of thermoacidophiles consist of Caldarchaeols (7).     
 
 
Figure 2. Chemical structure of Archaeol. (Ref: Patel, G.B. Sprott, G.D. (2006) Archaeal 





Figure 3. Chemical Structure of Cardarchaeol. (Ref: Patel, G.B. Sprott, G.D. (2006) Archaeal 
Membrane Lipids, Wiley, doi: 10.1038/npg.els.0004316) 
 
In the selected Archaea, Thermoplasma and sulfur-dependent thermophiles consist of head 
groups bound to core lipids of most caldarchaeol. The core glycerolipids of  
Sulfolobus sulfataricus and Thermoplasma acidophilum consist of up to 95 % caldarchaeols. 
The increased  amount of caldarchaeol stabilizes the membrane. Furthermore, the pentacyclic 
rings which can be found in Sulfolobus acidocaldarius and Thermoplasma acidophilum 
species have an crucial impact on stability against high temperatures. The core lipid of these 
species can contain up to 4 rings per alkyl chain (7). 
As mentioned above, the high stability of the native archaebacterial membranes can be 







nonitol tetraether (GDNT) (8) (Figure 4a, 4b). For the successful extraction of glycerol dialkyl 
nonitol tetraether (GDNT) from Sulfolobus acidocaldarious, we applied the extraction method 
proposed by Bode et al. and described in Chapter 2. The freeze-dried material of  
Sulfolobus acidocaldarious extracted with CHCl3:MeOH was then stirred with 
CHCl3:MeOH:5 % trichloroacetic acid (TCA) mixture. The mixture was washed thoroughly 






Figure 4. (a) Chemical structure of glycerol dialkyl nonitol tetraether (GDNT), (b) Chemical 
structure of GDNT with two cyclopentanes. (Ref: Shi-Lung, L, Charles E.M., Chang, E.L. 
(1989) Purfication of glycerol dialkyl nonitol tetraether from Sulfolobus acidocaldarius, , 
Vol:30  J Lip Res) 
 
The major class of archaeal lipids is bipolar tetraether lipids. Considering the stability 
properties of these lipids, it was proposed to employ them for the liposome formation to 
provide more durability to membranes compared to conventional liposomes (4). 
In 1959 E.G. Bligh and W.J. Dyer published a lipid extraction method (10). This Bligh-Dyer 







effective extraction of the total lipid amount from biomass. This total lipid mixture consists of 
a large variety of lipids of different configuration and properties. The mix of these lipids 
provides comprehensive stability of the liposomes which shows the inessentiality of 




Figure 5. Tetraether lipids general structure. (Ref: Albers, S.-V., van de Vossenberg, 
J.L.C.M., Driessen, A. J.M. Konings,W.N. (2000) Adaptation of the archaeal cell membrane 
to heat stress, Vol. 5, pp. 796-803 Front Biosci) 
 
 
1.2 Tetraether lipid liposomes 
Tetraether lipid liposomes are spherical soft-matter particles constructed from tetraether lipids 
instead of ester lipids. These lipids are extracted from archaeal membranes (12). The method 
of lipid extraction is mentioned above. Lipids of tetraether lipid liposomes consist of fully 
saturated phytanyl chains with 20-40 carbons in length. They are attached to the glycerol 
backbone via ether bonds (1) (Figure 5). Fully saturated bonds are playing an important role 













Figure 6. Monolayer-forming tetraether lipid and bilayer forming double chained lipid 
mixture in a liposome structure. (Ref: Réthoré, G., Montier, T. Gall T. Le, Delépine, P. 
Cammas-Marion, S. Lemiègre, L. Lehn, P. and Benvegnu, T. (2007) Archaeosomes based on 
synthetic tetraether-like lipids as novel versatile gene delivery systems,  pp.  2054-2056 Chem 
Commun) 
 
Liposomes have lately become a matter of particular interest as drug and gene carriers 
because of their biocompatibility and biodegradability properties. However, besides many 
advantages, one of the most important handicaps of liposomes concerns stability. So far, 
conventional lipids were incorporated with high amounts of cholesterol in their bilayers (14). 
Other methods include coating the lipids with polymers (15) or mixing with fluorinated 
phospholipids (16). With all these methods it was not possible to achieve sufficient stability. 
Tetraether lipids overcome this handicap due to their chemical properties, which do not exist 











1.3 Stability properties of liposomes 
High mechanical stability of tetraether lipids offers a wide range of potential usage in 
biotechnological applications, such as delivery systems. A significant stability is expected 
from gene or drug carriers, particularly if the environment of the destination has the potential 
to harm to the composition of the vesicle. For instance, a carrier for oral drug delivery in the 
gastrointestinal tract is expected to be stable at low pH and withstand protein degradation 
conditions (17).  
The gastrointestinal tract contains pancreatic fluids with 1.5-16.0 U of phospholipase A2 
activity in each ml (18). A drug loaded conventional liposome will undergo burst release 
when the lipids are hydrolyzed.  Similar to stability against bile salts, tetraether liposomes 
provide convincing results on stability against phospholipases (19). Besides that, several other 
stability studies with tetraether lipid liposomes were undertaken, among these, stability in 
alcohols, detergents, phenol, high salinity and combinations of those.  
The lipid mixture consists of a large variety of lipids with different properties. The mix of 
these lipids provides comprehensive stability to the liposomes which makes it an 
inessentiality to purify individual lipid species (11).  
Tetraether lipid liposomes are also convenient for storage; they do not fuse or aggregate at  
4° C for more than four months. It is as well possible to store them at higher temperatures and 
at a wide pH range  (20). 
The extreme stability of liposomes is attributed to the chemical structures of membrane lipids 
of Archaea. A typical biological membrane consists of a monolayer or bilayer of lipid 







aqueous medium surrounding the membrane. This hydrophilic head group is linked to the 
hydrophobic tails. These lipid molecules form a bilayer or monolayer membrane with van der 
Waals and Coulomb interactions. Non-covalent bonds in membranes provide higher 
impermeability to small ions (21). In consequence of this feature, high energy is required for 
transport of ions across the membrane. At higher temperatures the permeability will increase. 
It is expected that a conventional lipid membrane will be more permeable at higher 
temperatures. A tetraether lipid membrane provides an additional energy barrier to proton 
permeability. However, at a certain point of very high temperature, far upon the optimal 
growth temperature, the membrane will be unable to compensate the proton permeability. 
This proton permeability is strongly connected to the upper boundary of the growth 
temperature of the microorganism (22). On the other hand, sodium permeability is occurring 
via a solubility-diffusion mechanism (23). The bioenergetic role of protons is explained to be 
an environmental adaptation (24). For instance, Thermoplasma acidophilum grows in 
sulphuric acid ponds with a pH value of 2 at 59° C although its internal pH is 6.5 (25) and this 
internal conditions can only be maintained with a proton resistant membrane and an electron 
transport chain to protect the cytosol from irruption of protons (26). Hence, the proton 
pumping capacity of the membrane of aerobic thermophiles provides a high proton-motive 
force (27).  
Unusual physical and chemical properties of tetraether lipids increase the stability of archaeal 
membranes. These properties which were sustained to TEL liposomes make them attractive 
for biotechnology applications.  
High temperature stability enables heat sterilization of liposomes. However, most of the ester 
lipids cannot provide sufficient short and/or long term thermal stability. Thermal stability has 
been investigated by incubation of 5(6)-carboxyfluorescein (CF) and [
14
C] loaded ester and 







liposomes from Thermoplasma acidophilum compared to all other ester and ether lipid 
liposomes attributed to phase transition at low temperatures. 
For intravenous applications, stability of liposomes in serum and resistance against blood 
compartments is an important issue. In serum, bilayer-spanning and ether bonds of tetraether 
lipids provides better stability compared to other ester lipid liposomes (11).   
For successful drug delivery, stability against macrophages and other bioactive species is 
expected. However, it is reported that tetraether lipid liposomes can be taken up by 
macrophages in 50 fold higher concentration than other conventional lipids. This may appear 
as a disadvantage at first, yet it can be very useful in several biotechnological applications, 
such as antigen entrapped liposomes that cause an immune response which is currently 
achieved by toxic Freund’s adjuvant (28). As an option, radioisotope labelled liposomes can 
be used for macrophage targeting in nuclear medicine (29).   
High membrane stability may also inhibit the drug release in targeted tissue. Consequently, it 
is important to consider the circumstances and the environmental properties of the targeting 
region to determine the reasonable balance between stability and release of the entrapped 
agent in liposomes. 
 
1.4 Liposomal Drug Delivery Systems  
In 1968 Bangham has introduced membrane models with phospholipids where he indicated 
that phospholipids suspended into excess aqueous solution tend to spontaneously form bilayer 
vesicles, ―liposomes‖ (greek; ―fat bodies‖), and that their size and lamellar properties can be 
influenced by the preparation conditions (30). Since this discovery a number of liposomes 
were tailored with various lipids and lipid mixtures with modifications in size, physical, 







liposomes as drug carriers (31). Liposomes began to be used as industrial products in medical, 
pharmaceutical, food, cosmetic and other industries. Liposomes became especially attractive 
for the pharmaceutical industry because of their biocompatibility, non-toxic, non-
immunogenic and biodegradability properties and the scope of both hydrophilic and 
hydrophobic pharmaceutical incorporation, as well as the possibility of efficient delivery into 
cells and even into individual cellular compartments (32). Currently there are several drug 
incorporated liposome formulations available as pharmaceutical products. The main 
application range of these products lies within cancer treatment, reducing the serious toxicity 
and adverse side effects of anti-cancer drugs because the toxic drug can be entrapped into the 
liposome or incorporated to the lipid membrane. The liposome can even be targeted to the 







introduced in 1995 were considered to be the 
mile stones of liposome technology which successfully combined the basic research and 
industrial implementation. When incorporating anti-cancer drugs, they reduce systemic 
toxicity, early degradation or inactivation of the drug (33, 34). Hydrophilic drugs can be 
loaded to vesicles in aqueous solution; hydrophobic drugs can be incorporated into the 
amphiphile layer. In both cases, charge of the particles and interactions of the active 
compound with the vesicle forming molecules play an important role in drug entrapment and 
delivery. (35, 36). Besides the liposome formulation, the site of the administration of 
liposomes is considered to have a severe impact on delivery. Surface charge, serum proteins, 
lipoproteins and phagocytic systems may disturb the drug-liposome composition (36-38). 
Tetraether lipid liposomes allow long term blood circulation. Furthermore, liposomes are not 
only used intravenously but also in dermatological, pulmonary and oral applications. In this 
thesis, the stability of tailored tetraether lipid liposomes was addressed. As a consequence of 







low pH environment. These properties make them an adequate candidate for oral drug 
delivery. The vesicles are able to pass through the stomach without being damaged and can 
carry the loaded agent to further sections of the oral system (39). Conventional lipid vesicles 
are not able to resist phospholipase degradation and pass through the callus during topical 
application. Tetraether lipid liposomes are relatively resistant against phospholipase 
degradation (40) which may provide a method of long-term drug release in the dermatological 
application. 
 
1.5 Liposomal Drug Targeting Systems 
The currently used anti-cancer drugs are not able to differenciate between cancer cells and 
healthy cells. This results in a systemic toxicity and serious side effects. Drug targeting 
systems offer a less invasive alternative to the traditional anticancer therapy. Drug targeting 
strategies are classified into two groups: passive targeting and active targeting. Besides 
systemic administration, passive targeting involves the administration of the anti-cancer drug 
to the tumor baring organ or environment. Such procedures can be highly invasive because of 
the necessity of injection or surgical procedure. Another alternative of passive drug targeting 
is spontaneous drug accumulation in ―leaky‖ areas. Due to the increased permeability of the 
vascular endothelium of tumors, particles up to 500 nm can be accumulated into the interstial 
space (41, 42). Furthermore, systemic administration of liposomes causes limitations in 
applications because of rapid clearance from the bloodstream and uptake by 
reticuloendothelial system (RES) in liver and spleen (43). However, it is reported that, in 
comparison to free drug application, entrapped and modified liposomes exhibit significant 
changes in absorption, biodistribution and clearance (44, 45). Liposome size and surface 







circulation time in the plasma (46). On the other hand, when a rapid response on a selective 
cell type within a tissue is necessary, an active delivery system can facilitate this aim. Active 
targeting strategies of liposomes are based on ligand-bearing liposome application. As ligands 
one can use antibodies, carbonhydrates, hormones, polypeptides, drugs, growth factors, 
glycoproteins, cytokines, toxins or lectins. (47). The best known  ligand interactions can be 
classified as ligand-receptor interactions, antibody-antigen interactions and lectin-
carbonhydrate interactions, protein-ligand interaction, metal-ligand interaction, integrin-
ligand interaction (48). Lectins are nonimmunological proteins and liposomes can be 
modified effectively with these lectins and used to target cell surface carbonhydrates (49). In 
this respect, Concanavalin A is the first lectin to be purified on a large scale and available on a 
commercial basis; it was extracted from the jack bean  
Canavalia ensiformis and carries two metal binding sites, also it is one of the Mannose 






Figure 7. Concanavalin A (at neutral and alkaline pH, ConA exists as a tetramer of four 
identical subunits of approximately 26,000 daltons each. Below pH 5.6, ConA dissociates into 








One of the binding sites binds to sugar domains localized on inflamed tissues or tumors, the 
other binding side can be covalently bound to the liposome (52). Effective targeting of a drug 
carrier reduces adverse effects and provides higher impact on cancer therapy with a lower 
dose of drug.  
The ligand conjugation of tetraether lipids serves this scope. In this thesis, covalent binding of 
ConA to the active lipid containing liposome was investigated. Tetraether lipids were 
activated with cyanuric chloride in the presence of chloroform and ConA was bound to the 





Figure 8. Concanavalin A conjugated tetraether lipid. 
 
1.6 Liposome based drug delivery in Cancer Therapy 
Since liposomes were discovered they have drawn the attention of researchers as potential 
carriers  of various drugs and bioactive molecules in the therapeutical and diagnostical fields.  
The pharmaceuticals especially developed for cancer treatment are currently not able to 
specifically target inflamed cells. Liposomal drug targeting provides a better mode of cell 







by drug-lipid interactions of hydrophobic substances and drug trapping of hydrophilic drugs. 
Liposomal drug delivery provides the opportunity of longer systematic circulation of 
cytotoxic drugs and delivery to certain extravascular regions (55, 56). Recent studies showed 
that liposomes decrease the toxicity of several antitumor drugs due to the kidney uptake 
compared to the free drug. Also, by the encapsulation of drug, a much lower amount of drug 
is sufficient for effective therapy (57, 58). That also prevents the side effects caused by 
application of high doses of the drug. Liposomes also protect the drug from rapid degradation 
and exhibit higher efficiency compared to their free counterparts (59).  
 
1.6.1 Angiogenesis 
It is well known that for solid tumor growth, blood is essential for the suppliment of oxygen 
and nutrients. Under normal conditions, angiogenesis, the formation of new blood vessels, 
occurs in adults during the ovarian cycle, wound healing and other physiological processes 
during repair (60). Most of the tumors over a size of 1-2 mm
3
 cannot survive without a blood 
vessel supply. Therefore in 1972 Folkman has explained the necessity of angiogenesis for 
tumor progression (61). At first view, angiogenesis seems to be the same as vasculogenesis. In 
fact, during vasculogenesis the blood vessel formation occurs by de novo production of 
endothelial cells. Angiogenesis on the other hand is a term to denote the formation of new 
blood vessels from pre-existing ones (62). It has been found that the tumor cells induce 
angiogenesis (63). It was also reported that angiogenesis plays a critical role not only in 
formation and maintainance of the primary tumor but also in its metastasis (64). Since then, 
anti-angiogenesis is regarded as a cancer therapy strategy. During the formation of a new 
blood vessel, the endothelial cell, the basement membrane and the extracellular matrix should 







prepared by stromal cells. The proliferation and migration of endothelial cells is linked to 
growth factors. The endothelial cells then form a tube-like structure, where the blood flows 
through. Hence, studies of anti-angiogenesis were focused on the major factors that regulate 
angiogenesis such as the basic fibroblast growth factor (bFGF or FGF-2) and the vascular 
endothelial growth factor (VEGF). The VEGF family consists of sub-types such as VEGF-B, 
VEGF-C, VEGF-D and isoforms such as VEGF121, VEGF165 (66). Unlike bFGF, VEGF is 
expressed by the vast majority of cancers. In the case of blocking its activity, the tumor 
growth in vivo is inhibited (67). Beside bFGF and VEGF, the other factors and proteins 
effecting the angiogenesis are Platelet-derived growth factor (PDGF) which plays significant 
role in blood vessel formation, Transforming growth factor beta (TGF-β) which controls 
proliferation, and cellular differentiation, Angiopoietin 1 and integrins which are related with 
vascular development, Platelet Endothelial Cell Adhesion Molecule (PECAM-1) which is 
expressed in certain tumors for the tissue regeneration (68).  
In this thesis, ―imatinib (STI 571)‖ as an anti-angiogenic inhibitor is used. Besides cell 
proliferation, imatinib inhibits VEGF production. In the case of inhibition of VEGF 
expression, a large range of anti-tumor effects could be provided. Therefore VEGF expression 
is particularly investigated in this thesis.  
VEGF is a disulfide-bonded dimeric glycoprotein. VEGF has various isoforms with a 
molecular mass of 34-45 kDa (69). These isoforms are responsible for identical biological 
activities (70). Dvorak and colleagues have discovered that VEGF has an important role in 
vascular permeability. It was reported that VEGF is normally expressed at low levels by most 
human and animal tissues during the growth process, and it is only under abnormal 
conditions, such as pregnancy and tumor existence, that the expression of VEGF is found to 







angiogenic inhibitors were developed and tested over the years. Many of these drugs were 
already in use as anti-cancer drugs, but anti-angiogenic effect of these drugs were then 
described by Folkman, Klement and their colleagues (71, 72). 
 
1.6.2 Tyrosine Kinase Inhibition 
In cancer and benign proliferative disorders, protein-tyrosine kinases play a fundamental role 
in signal transduction (73). Their blocking by substances like the tyrosin kinase inhibitor 
imatinib can affect the tyrosine kinase signal cascade. Imatinib mesylate (Glivec
®
 STI571, 
also known as imatinib) is a phenylaminopyrimidine analogue that binds to the ATP-binding 
site of a specific tyrosine-kinase (74). Although imatinib was first developed as a platelet-
derived growth factor receptor- α inhibitor, it was later found that imatinib also inhibits the 
BCR-ABL, c-KIT (75-78). Imatinib is specific for the tyrosine kinase inhibitor domain in the 
abl (Abelson murine leukemia) gene. In diseases such as chronic myelogenous leukemia, the 
Philadelphia chromosome leads to a fusion protein of abl with bcr (breakpoint cluster region) 
gene which causes a constitutively active tyrosine kinase. Imatinib binds to the tyrosine 
kinase domain of this fusion protein competitively.  Lately it was also reported that imatinib 
reduces the Bcr-Abl complex mediated secretion on VEGF. This thesis investigated the 















Figure 9. Imatinib (CGP57148B or STI-571). (C29H31N7O) (Ref: http://de.wikipedia.org/ 
wiki/imatinib) 
Currently imatinib is used for treatment of chronic myeloid leukemia (CML), malignant 
gastrointestinal tumors (GIST) and bone marrow (BM). Case studies reported that with most 
BM patients a significant improvement due to the imatinib-related effect was observed (82). 
Shortly after that, it was reported that the imatinib treatment reduces the VEGF expression. 
Hence, the improvement on BM can be explained with the anti-angiogenic property of 
imatinib, due to the significant correlation of BM cells and VEGF plasma levels in the 
patients (83). It has also been stated that the use of imatinib could induce anti-angiogenic 
and/or anti-vascular effects in GIST (84). It is clear that prevention of angiogenesis is 
essential to suppress tumor progression. Therefore imatinib is promising for the approach of 
anti-angiogenesis as a novel anti-cancer strategy (83, 85, 86). Like other anti-cancer 
pharmaceuticals, imatinib has also many serious side effects. Neutrophenia, 







effects of imatinib (81, 87). Therefore liposomal encapsulation is essential to reduce the side 
effects of anti-cancer drugs like imatinib (88). 
 
1.7 The Chorioallantoic Membrane 
For the screening of angiogenesis and anti-angiogenesis, an easy, reproducible, rapid and low 
cost assay was investigated by tissue engineers. For decades, in vivo assays such as rodent air 
sac, iris and vascular cornea as well as hamster check pouch and rabbit ear chamber have been 
used (89). Unfortunately these assays are relatively time consuming and expensive. When 
assessing alternative angiogenesis assays, the Chorioallantoic Membrane (CAM) Assay seems 
to be very appropriate for both angiogenesis and anti-angiogenesis studies (90). CAM is an 
extraembryonic membrane of the chicken egg, which mediates gas and nutrients exchange to 
the embryo and has a very dense capillary network. The immunocomponence of the chick is 
not fully developed during the embryo stage; this means the rejection system is not yet 
exerted (91). Besides real-time angiogenesis imaging, the CAM assay has an easy 
methodology, requires no sterility and is much cheaper than the other methods. Since 1976 
various cell implantations such as melanoma, neuroblastoma, and carcinoma have been 





















Figure 10. Chicken egg components (Ref: www.enchanedlearning.com ) 
 
It is known that solid tumors are not able to form blood vessels on their own, they need to 
elicit the production of these vessels from the host. The CAM assay provides a clear 
monitoring system that allows the observation of new vessels arising from the host and 
growing towards the tumor (95). The tumor can transfer this signal over a distance of up to  
5 mm. If a micro vessel fails to penetrate the tumor until the 3
rd
 day of implantation, the tumor 
remains pale (96). Tumor induced micro vessels are tiny and have short half-lifes. If the 
stimulus is turned off, they regress quickly (97). Therefore the anti-angiogenesis effect of an 










applied to determine the anti-angiogenic effect of a tyrosine kinase inhibitor. The effect of the 






















The objectives of this thesis are the preparation and characterization of liposomal drug 
targeting and drug delivery models based on very stable tetraether lipids. Archaeal tetraether 
lipids are very promising to improve the stability of the current liposomal drugs in the 
pharmaceutical field. Thus, the initial objective of this thesis can be stated as ―the 
investigation of stability properties of TEL liposomes under various conditions to reveal 
whether they meet the requirements of medical applications.‖ It is known that conventional 
liposomes have several drawbacks such as low stability against high temperature, low pH  
values, biological media and high fusion tendency with biological barriers. Therefore 
extremely stabile liposomes were tailored with tetraether lipids. Tetraether lipids were 
isolated from archea species, which have extreme stable cell membranes stabile in low pH and 
high temperature mediums. The impact of the tetraether lipid in the composition of liposomes 
was investigated to overcome the drawbacks to provide stabile long-circulating liposomes to 
be used in oral and pulmonary systems.  
Another objective of this thesis concerns the minimization of the damaging systemic side 
effect and toxic effect of drugs and provide rapid therapy with minimum dose of drug. 
Therefore surface modified TEL liposomes were investigated to serve as ligand-carbohydrate 
interaction model for site specific targeting of stabile TEL liposomes. This model simulates 
the interaction of lectin modified TEL liposomes with sugar residues surrounding the cells. 
Binding efficiency of the lectin conjugated TEL liposome was discussed. Subsequently, a 
protein-tyrosine kinase inhibitor „Imatinib―(Glivec
®
- STI 571) was entrapped into tetraether 







Thereby, the anti-angiogenesis effect of the inhibitor can be provided with less drug dose 
compared to free drug.  
Lately it was reported that imatinib could also induce antiangiogenic and/or antivascular 
effect. For this purpose, imatinib encapsulated TEL liposomes were investigated on a very 
effective and simple angiogenesis model, known as ―Chorioallantoic membrane model‖. 
Consequently, to determine the anti-angiogenic effect of imatinib entrapped TEL liposomes 
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2.1  Abstract  
Liposomes are widely investigated for their applicability as drug delivery systems. However, 
the unstable liposomal constitution is one of the greatest limitations, because the liposomes 
undergo fast elimination after application to the human body. In the presented study, novel 
archeal lipids were used to prepare liposomal formulations which were tested for their 
stability at elevated temperatures, at different pH-values and after heat sterilization. 




















Liposomes are bilayered spherical membrane structures which are promising for 
pharmaceutical and diagnostic use (1). However, there are limitations of the usage of 
liposomes which is mainly caused by their low stability (2). To reduce this problem, in this 
study an archael lipid, Glycerol Dialkyl Nonitol Tetraether lipid (GDNT) (see Fig. 1) is 
chosen to prepare highly stable liposomes. The GDNT is isolated from  
Sulfolobus acidocaldarius (3). Archaea are one of the three major domains of life (4). The 
major difference of these archaea from bacterial and eukaryotic cells is their membrane lipids 
(5). Archaea do not have any cell wall nevertheless the properties of the cell membrane lipid 
provide a remarkable long-term stability (6). The archaea are divided into phenotypes of 
methanogens, halophiles and thermophiles. The lipid used in this study is from a type of 
thermophilic archaea. Sulfolobus acidocaldarius is a well studied extremely thermophilic 
archae with the optimal growth conditions of 70–80° C and pH 3 (7, 8). These archael 
membrane lipids consist of monopolar ether head groups and saturated, branched phytanyl 
chains which are mainly attached to the glycerol backbone carbons through ether bonds. This 
chemical structure provides high stability due to low oxidation capacity and hydrolytic 
resistance (9). Liposomes can incorporate hydrophilic and lipophilic drugs and reduce the 
overall dose and amount of side effects by specific targeting. Also, the relatively stable 
structure of GDNT liposome offers new range of applications. Liposomal formulations made 
of GDNT are able to protect the pharmaceuticals from biochemical degradation or 
metabolism. Therefore, they are interesting for oral applications. Kimura reviewed that a 
significant quantity of drug entrapped into liposomes can be absorbed by the small-intestinal 







stability of liposomes in the acidic milieu of the gastrointestinal tract and their absorption 
therein (11). Pulmonary drug delivery is also applicable using liposomes, because they are 
absorbed through the thin layer of alveolar epithelial cells (vast surface for an adult is  
43–102 m
2
) (12–14) and transported into the systemic circulation (15–17). However, the 
inhaled objects can be eliminated by macrophages from the alveoli surface when they are 
bigger than 260 nm (18). For the future aspects of tetraetherlipid liposomes, there are still 
some details to be clarified. This article is concerned with the stability of GDNT liposomes 





Figure 1. GDNT Glycerol Dialkyl Nonitol Tetraetherlipid. (Ref: Lo, S.-L. Montague, C. E.,  
Chang, E. L. (1989) Purfication of glycerol dialkyl nonitol tetraether from Sulfolobus 
















2.3.1 Extraction and Hydrolysis of the Tetraether Lipids 
 
 
1. 25 g Freeze-dried biomass from Sulfolobus acidocaldarius (BHP Billiton, Global 
Technology, Perth Technology Centre, Australia), store at –20° C.  
2. Chloroform (CHCl3): methanol (MeOH) : 5 % trichloroacetic acid (TCA) mixture (1:2:1 
v/v). Store at RT. 
3. MeOH:H2O mixture (1:1 v/v). Store at RT. 
4. 100 ml 1 M methanolic hydrochloric acid. Store at RT. 
5. 8 M KOH is prepared to adjust the pH level to pH 14 and to adjust the pH level to pH 3  
32 % HCl is prepared. Store at RT. 
 
2.3.2 Separation of the GDNT 
1. A chromatography column with a diameter of 4 cm (conventional glass) is filled with 300 g 
silica gel 60 (Merck, Germany) for separation of lipid fractions. 
2. The eluents used are CHCl3 followed by CHCl3:diethyl ether (8:2 v/v) and CHCl3: MeOH 
(8:2 v/v), according to Lo et al. (19). 













2.3.3 Liposome Formulations 
1. Phospholipon 90 G (Lipoid, Germany) is dissolved in CHCl3:MeOH (3:1 v/v) to achieve a 
final concentration of 10 mg/ml solution. 
2. For hydrolysis, ultrapure, bidistilled water (pH 5.5) is used. 
3. Nylon syringe filters with the pore size of 0.45 μm are supplied from Rotilabo Roth (Carl 
Roth Karlsruhe Germany). 
4. The Extruder is supplied from Avestin Europa GmbH with polycarbonate membranes of  
19 mm diameter and 100 nm pore diameter. 
 
2.3.4 Stability Tests of Liposomes 
1. For the pH stability studies pH 2.0 solution (50 ml 0.2 M KCl is adjusted with 0.1 M HCl), 
pH 4.0 solution, (100 ml 0.1 M potassium hydrogen phthalate is adjusted with 0.1 M HCl)  
pH 7.4 buffer (129 mM NaCl, 2.5 mM KCl, 7.4 mM Na2HPO4, 1.3 mM KH2PO4) and pH 9.0 
(100 ml 0.025 M NaB4O7, 9.2 ml 0.1 M HCl) are prepared. 
 
2.3.5 Atomic Force Microscopy 
1. As substrate for the sample preparation, silicon wafers from Wacker Chemie AG (Munich, 
Germany) with a natural silicon oxide layer (thickness 3.8 nm) and a surface roughness of  
0.3 nm is used. The wafers are split into small pieces of about 1 × 1 cm. The pieces are 
cleaned in a bath sonicator for 20 min in CHCl3:MeOH (2:1, v:v), then they are dried in a air 







2. NSC 16/Cr-Au cantilevers from Anfatec Instruments AG (Oelsnitz, Germany) with a 
nominal force constant of 45 N/m, resonant frequency of 170 kHz and a length of 230 μm are 




2.4.1 Extraction and Hydrolysis of the GDNT Lipids 
1. Different methods for the extraction and purification of the GDNT are established. We used 
the combined extraction and hydrolysis method according to Bode et al. (20) 
2. 25 g freeze-dried biomass from Sulfolobus acidocaldarius grown at 68° C, is transferred 
into a 1 l flask and into this flask 400 ml of a CHCl3:MeOH:TCA mixture is added.  
3. The mixture is heated to a gentle reflux temperature of 60° C for 2 h. 
4. After cooling down to room temperature, the mixture is filtered. The filter cake is 
transferred back to the flask and kept at 60° C in the same solvent mixture as before. This 
procedure is continued for three more cycles. 
5. The collected extractions (upper green layer of precipitate and a clear brown colored 
solution) are washed with a mixture of MeOH:H2O (1:1, 800 ml). 
6. From the combined chloroform extracts, the solvent is evaporated in vacuum at elevated 
temperatures. 
7. 100 ml 1 M methanolic HCl is added to the residue and this is heated at 80° C for 16 h. 
8. Then the reaction mixture is cooled down to room temperature and 100 ml water is added. 
The pH of the resultant mixture is adjusted to 14 using 8 M KOH. 
9. The mixture is subjected to base hydrolysis at 80° C for 1 h, and cooled down to room 







10. The resultant mixture is extracted with CHCl3 (3 × 200 ml). The chloroform extract is 
separated, dried with magnesium sulfate and solvent evaporation under vacuum to yield a 
brown lipid residue. 
 
2.4.2 Separation of the GDNT 
1. The separation of 8 g of the hydrolysed lipid fraction from the total lipid extraction is done 
via silica gel 60 column chromatography. 
2. The samples are collected (50 ml fractions) and their lipid composition is analyzed by thin 
layer chromatography. The lipids are stained by the use of methanolic sulfuric acid followed 
by an ashing process. The lipid is visible as dark spots. GDNT shows a Rf value of 0.45 
(CHCl3 : MeOH, 9:1, v:v) in accordance to literature (0.45 (19) and 0.35 (20)). 
3. The fractions containing GDNT are collected and the solvents are evaporated at elevated 
temperature. The purified lipid is stored at –20° C before use. 
  
2.4.3 Preparation of Liposomes 
1. Preparation of liposomes conducted with different molar ratios of GDNT and 
Phospholipon. As a stock solution, Phospholipon is dissolved in chloform:methanol (2:1, v/v) 
and 10 mg/ml solution is prepared. 
2. Different liposome compositions are prepared (see Fig. 2) 
3. The liposome preparation procedure is based on film formation and hydration. After 
transferring the mixture of Phospholipon and GDNT solutions into 10 ml round bottom flasks, 
the chloroform-methanol solution is removed by evaporation at 300 mbar and 45° C to obtain 







4. For hydration, bidistilled water is used to prepare the liposomes in the concentration of  
10 mg/ml. To form the lipid vesicles, a bath sonicator at 45° C is used. After obtaining a 
dispersion of the lipid in water, sonication is continued with a probe type sonicator to increase 
the energy input. For the following processes, the sample is transferred into a 50 ml plastic 
tube. 
5. Sonication is continued for 8 min (30 s sonication followed by 30 s rest). The power was 
set to level 6. (see Notes 1 and 2). If a clear dispersion is not achieved, the sonication can be 
continued. 
6. After sonication the samples are filtered by syringe filters with the pore size of 0.45 μm to 
separate large vesicles that may blockade the extruder membrane (see Note 3). 
7. For the preparation of ~100 nm liposomes, the formulations are extruded through a 0.1 μm 
polycarbonate membrane. Preheating of the extruder above the main phase transition of the 
lipid mixture (40° C) is essential to provide an effective liposome extrusion (see Note 4). The 
extrusion is conducted 21 times to each sample. The achieved liposomes have a diameter of 
100–150 nm. If the initial size measurements verify larger diameters, the extrusion can be 
repeated 11 times more. 
8. All the size measurements in this study are performed on a Zeta Sizer (Malvern instruments 
GmbH, Germany). The diluted liposomal formulations (10:60, v:v, bidistilled water) are 
measured in a micro cuvette (Malvern instruments GmbH, Germany). 
9. Zeta potential measurements are also performed on the Zeta Sizer. All samples are diluted 
1:10 (v:v) with water. A folded electrophoresis cell is used (Malvern instruments GmbH, 
Germany) for Laser Doppler Anemometry (LDA) measurements. 
10. The cuvette or electrophoresis cell is placed in the Zeta Sizer and allowed to equilibrate to 







11. The manufacturer’s software automatically adjusts the Laser attenuation and measurement 
position. For each size and zeta potential determination, 3 measurements consisting of 6 sub 
runs with duration of 10 s are averaged. 
12. In Fig. 2, the initial diameter and zeta potential values of liposome formulations are 
presented. 
 
2.5 Stability Testing 
2.5.1 ThermostabilityTesting 
1. After measuring the initial diameters and the zeta potentials of liposomes, from each 
composition, 100 μl aliquots are mixed with 600 μl bidistilled water, in a glass tube. 
2. The samples are transferred into a metal tube holder and incubated at 36° C, 60° C, and  
100° C for 4 h in a cabinet heater.  
3. After incubation, when the samples are at room temperature, the diameter values are 
determined with Zeta Sizer. 
4. The results of thermostability tests are presented in Fig. 2. 
 
2.5.2  Stability During Autoclavation 
1. The autoclavation is performed on a standard autoclave 3850 ELC (Systec GmbH, 
Germany). 
2. Due to the properties of high thermostability the autoclavation of liposomes were 
considered to be applicable, which brings large sterilization possibilities along with. 
3. Before autoclavation, the liposome samples were diluted with bidestilled water in the ratio 







4. The samples were loaded into the autoclave and treated with a standard autoclave 
procedure for solutions (15 min at 121° C, 29 psi pressure, saturated steam). 
5. The size measurements in Fig. 2. It could be shown that the liposomal formulations 
containing GDNT can be autoclaved. The diameter is relatively constant. 
 
2.5.3 pH Stability 
As a first test for the stability of the formulations in the gastrointestinal tract, liposomes are 
incubated in solutions of different pH-values mimicking the gastrointestinal environment. 
1. pH stability tests are performed by incubating the liposomes in different solutions. From 
each liposomal formulation, 100 μl aliquots are incubated in 600 μl of pH 2.0, pH 4.0, pH 7.4, 
pH 9.0 buffer solutions. 
2. The initial diameters and zeta potentials are measured with a Zeta Sizer (Malvern 
Instruments, Germany, HeNe Laser 633 nm, 173° C scattering angle, 25° C) right after 
mixing the liposomes with buffer solutions. 
3. After 4 days of incubation, hydrodynamic diameters are determined as it is explained in 
Chap. 2.4.3. 
4. With the size measurements, the effect of GDNT stabilizing effect is shown. The results are 
presented in Fig. 2. With the increase of GDNT molar ratio, the liposome size is much more 














Figure 2. Different liposomal formulations containing the tetraether lipid GDNT are 
characterized regarding their stability. The initial diameter ranged from 69 nm for the mixture 
9:1 GDNT:Phospholipon to 137.5 nm for the pure GDNT. The negative zeta potential is 
representative for all liposomal formulations. (a) The stability according to the liposomal size 
of the liposomes iss tested at different temperatures. The measurements are done after 
incubating 40 μl liposome solutions in 240 μl bidestilled water for 4 h. The results show the 
stabilizing effect of GDNT content in the liposome structure. (b) The diagram represents the 
stability of particles after autoclavation. The samples are incubated 15 min at 121° C and  











2.6  Atomic Force Microscopy 
1. Atomic force microscopy (AFM) is performed on a Digital Nanoscope IV Bioscope (Veeco 
Instruments, Santa Barbara, CA). The AFM is vibration and acoustically damped (21). All 
measurements are performed in tapping mode. The applied force to the sample surface is 
adjusted to a minimum to avoid the damage of the sample. The sample is investigated and 
scanned under constant force. The scan speed is proportional to the scan size and the scan 
frequency is between 0.5 and 1.5 Hz. Images are obtained by displaying the amplitude signal 
of the cantilever in the trace direction, and the height signal in the retrace direction, both 
signals being simultaneously recorded. The results are visualized either in height (the real 
height of the sample in a resolution on 0.3 nm) or in amplitude mode (the damping of the 
frequency signal). 
2. Various methods are available for sample preparation. A very convenient procedure for the 
preparation of liposomes is the self-assembly technique (22). Small pieces of silicon wafers 
(about 1 × 1 cm) as substrate material are placed into the sample dispersion for 20 min at 
room temperature and the liposomes are allowed to adsorb to the surface under equilibrium 
conditions. The silicon substrates are removed from the dispersions. The samples are dried at 
room temperature and investigated within 2 h. 
3. The liposomes containing GDNT are stable against the substrate surface, while 
conventional liposomes tend to spread to the surface and form a supported lipid bilayer as 
















Figure 3. Visualization of the liposome morphology and size distribution determined with 
AFM and Zeta Sizer. (a, b) Pure phospholipon liposomes adhered on silicon wafer as 
substrate. The liposomes have diameters between 80 and 250 nm with an average diameter of 
178 ± 12 nm. The liposomes tend to spread to the surface, because of the low membrane 
stability. (c) Pure GDNT liposomes with an average diameter of 137 ± 8 nm  
(PDI 0.295 ± 0.017) and a zeta potential of –15.3 ± 0.60 mV. The liposomes are stable and 
show a spherically, round shape. (d) Size distribution of the pure GDNT liposomes measured 











2.7  Notes 
 
1. The container should be small enough so that the sonicator probe can immerse deeply  
(1–2 cm) in the sample but large enough so that the probe does not touch the sides or bottom 
of the container. 50 ml plastic tubes with round bottoms are used. 
2. Probe type sonication heats the solution very quickly; to avoid damage of lipids and 
liposomes, an ice bath in a beaker is prepared and placed securely on a ring stand in the sound 
proof box of the sonicator. 
3. For the filtration of liposome solutions the whole sample is transferred through the filter 
into plastic tubes. 
4. When working with an extruder, it is important to assure that the retainer nuts are tight to 
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3 New Highly Stable Liposomal Formulations Based On 
Tetraetherlipids From The Archaeon  










3.1 Abstract  
Background: Liposomes prepared with tetraether lipids (TEL) are considered to be more 
stable than conventional liposomes. In this study, the stability of tetraether lipid liposomes 
from Thermoplasma acidophilum was investigated under conditions simulating the 
pulmonary system and gastrointestinal tract. A number of molar ratio formulations of 
TEL:Phospholipon 100H (Ph) were compared in each condition.  
Materials and Methods: The liposomes were exposed to various temperature and pH 
conditions. The effect of these conditions on the stability of liposomes was investigated by 
zeta size, zeta potential and morphological assessments. The effect of autoclaving on 
liposome stability was observed. Moreover, 5(6)-Carboxyfluorescein (CF) release was 
measured after the incubation in Fetal Calf Serum (FCS) and Alveolar Surfactant medium. 
Results: According to the analysis of different TEL:Ph liposome formulations, it was 
indicated that TELs endow improved physical properties. The contribution of TELs to 
liposome properties was shown to have a significant impact on stability against low pH and 
sterilization by autoclavation. The stability of 10:0 molar ratio Tetraether:Phospholipon 100H 
(TEL:Ph) liposomes was confirmed with AFM before and after FCS incubation according to 
their size and morphology.  
Conclusion: It could be concluded that the contribution of TEL with increasing molar ratio in 
the TEL:Ph liposome formulations resulted in increasing structural stability under high 
temperature, low pH, autoclave and lung surfactant conditions.  











Liposomes are spherical lipid membranes consisting of one or more lipid layers. These lipid 
layers have hydrophilic and hydrophobic compartments (1). Conventional liposomes have an 
attractive potential for constructing tailor-made vehicles because of their enormous versatility 
in particle size and other physical parameters. Biocompatible properties allow them to be used 
as delivery systems for drugs, proteins, plasmid DNAs, antisense oligonucleotides or 
ribosomes, as well as for biochemical, pharmaceutical and cosmetic purposes. Besides the 
non-pathogenic and non-immunogenic features, their production is of relatively low cost; 
therefore they are appropriate for drug delivery on medical applications such as parenteral, 
transdermal, and pulmonary application.  
However, some drawbacks are observed especially in case of liposomes composed of 
distearoylphosphatidylcholine or dipalmitoylphosphatidylcholine, phosphatidylserine and 
cholesterol. These drawbacks are (i) low stability at low pH values, (ii) low stability against 
biological media (such as FCS or surfactant), (iii) high fusion tendency with biological 
barriers and (iv) their rapid clearance by the reticulo-endothelial system (RES) or fast 
metabolism (2).  
It is known that archaeal liposomes which include saturated bipolar tetraether lipids are more 
stable than liposomes formed of bacterial or eukaryotic lipids (3, 4). To overcome the stability 
drawbacks of classical liposomes, liposomes with tetraether lipids from  











Figure 1. Tetraether lipids general structure. (Ref: Albers, S.-V., van de Vossenberg, 
J.L.C.M., Driessen, A. J.M. Konings,W.N. (2000) Adaptation of the archaeal cell membrane 
to heat stress, Vol. 5, pp. 796-803 Front Biosci) 
 
Thermoplasma acidophilum is a thermoacidophilic archaeon, first isolated in  
1970 by Darland et al. (6). The optimal living conditions for  
Thermoplasma acidophilum are at pH 2 and at a temperature of 59° C. The specific structure 
of lipids composing the cytoplasmic membrane of these archaea allows them to sustain the 
extreme environmental conditions. The lipid constitution of archaeal membranes contain ether 
bonds and varying numbers of cyclopentanes in the hydrocarbon chains providing thus a 
higher aqueous dispersity and expanded bilayer membrane (3, 4). Furthermore archaeal lipids 
do not contain double bonds. These properties distinguish archaea species like  
Thermoplasma acidophilum from bacterial species (7). 
Liposomes prepared with archaeal lipids offer a wide range of medical and pharmaceutical 
applications due to their enhanced stability properties. When incorporating a hydrophilic and 
lipophilic drug, liposomes become an attractive tool for reducing overall drug dose and 
decreasing side effects. According to Kimura, a significant quantity of drug entrapped 







investigations are necessary for characterization of liposome stability properties in acidic 
milieu of the gastrointestinal tract and their absorption therein (9). Certainly the most 
important criterion of a well-designed vesicle to be used in oral delivery is the ability to 
survive in the environment of the gastrointestinal tract. As a result of low pH values most 
conventional lipid liposomes undergo complete disintegration forming a mixture of soluble 
micelles (10, 11). 
The pulmonary system is attractive for a liposomal drug delivery system too. When smaller 
than 260 nm, liposomes can be absorbed on a large surface of alveolar epithelium. Particles 
larger than 260 nm are likely to be destroyed by the macrophage system of the lung (12). 
Another criterion that affects stability in the pulmonary system is the influence of the natural 
surface surfactant of the lung. Hence, in this study, liposome stability was investigated during 
exposure to the commercial lung surfactant Alveofact (13). 
This study addresses the stability properties of tetraether lipid liposomes in comparison to 
phospholipid liposomes, which provides a perspective on further usage of tetraether lipid 

















3.3 Materials and Methods 
3.3.1 Materials 
Freeze-dried biomass from Thermoplasma acidophilum was a kind gift from SIT GmbH and 
Interface Technologies (Rosenhof/Heiligenstadt, Germany), it was stored at –20° C until 
usage. Phospholipon 100 H (Ph; commercial phosphatidylcholine including stearic and 
palmitic acid) and 5(6)-Carboxyfluorescein (CF) were purchased from Lipoid GmbH 
(Ludwigshafen, Germany) and Fluka, (Buchs, Switzerland), respectively. Fetal Calf Serum 
(FCS) was obtained from PAA (Coelbe, Germany), Triton X-100 was provided by Carl Roth 
(Karlsruhe, Germany). Chloroform (CHCl3) and methanol (MeOH) were both purchased from 
Carl Roth (Karlsruhe, Germany) and the Chloroform:Methanol (CHCl3:MeOH) (2:1 v/v) 
mixture was stored at room temperature until it was used. 
HEPES buffer solution (HBS) was prepared with 40 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), 5 mM Glucose (Dextrose) and 120 mM NaCl and adjusted to 
pH 7.4. Phosphate buffer solution pH 7.4 had the composition of 1.3 mM KH2PO4, 7.4 mM 
Na2HPO4 x 2H2O, 129 mM NaCl, 2.5 mM KCl and dissolved in bi-distilled water. The rest of 
the chemicals not mentioned separately were purchased from Thermo Fischer Scientific 
(Schwerte, Germany) and Carl Roth (Karlsruhe, Germany). 











3.3.2 Extraction of the tetraether lipids 
Tetraether lipids (TEL) were extracted from 10 g freeze-dried biomass of  
Thermoplasma acidophilum according to a modified method of Bode et al. (14). The biomass 
was transferred into a 1 L flask and mixed with 500 mL CHCl3:MeOH (2:1 v/v). The mixture 
was heated to a reflux temperature of 60° C for 12 hours. After cooling down to room 
temperature, the mixture was filtered through 300 g silica 60 (Merck, Germany). The filter 
cake was transferred to the flask and refluxed for another 12 hours. After filtration, the solvent 
from the resultant mixture was evaporated under vacuum to yield a lipid residue. This residue 
consists of total lipid fraction. From this total lipid fraction, 10 mg/mL tetraether lipid 
solution in CHCl3:MeOH (2:1 v/v) was prepared.  
 
3.3.3 Preparation of liposomes 
Phospolipon 100 H (100 % saturated phosphatidylcholine) was dissolved in CHCl3:MeOH 
(2:1 v/v) to prepare a 10 mg/mL stock solution. Liposome suspensions were prepared in molar 
ratios of 10:0, 7:3, 5:5, 0:10 Tetraether lipid: Phospholipon 100 H (TEL:Ph). These 
suspensions were transferred to 10 mL round bottom flasks and evaporated at 45° C 300 mbar 
with a rotary evaporator (Heidolph, Laborota 400, Schwabach, Germany) to obtain a lipid 
film. First the thin film was hydrated with bi-distilled water containing 0.9 % NaCl.  To 
obtain a homogeneous suspension of the liposomes in water, the solution was sonicated with a 
probe type sonicator with an increased energy input. (G. Heinemann Ultraschall und 
Labortechnik Schwöbosch, Germany) sonication was applied (for 8 min, 30 sec sonication 







through a pore size of 0.2 µm. Finally all the liposome suspensions were extruded 21 times 
through a 0.1 µm polycarbonate membrane filters by a mini extruder device. (Avanti, 
Hamburg, Germany)   
 
3.3.4 Preparation of 5(6)-Carboxyfluorescein encapsulated liposomes 
CF liposomes were also prepared according to the solvent evaporation method. The related 
liposome compositions with the same molar ratios were rotary evaporated at 45° C, 300 mbar 
with a rotary evaporator. The liposomes were hydrated with PBS, pH 7.4 which contained  
50 mM CF. After hydration the same procedure was applied as mentioned above. The  
% encapsulation efficiency (% EE) was calculated with the equation of:  
  
where Cout defines the fluorescence intensity not encapsulated in liposomes, and Ctotal is 
corresponding the value after adding Triton X-100 in order to disturb the liposomes to find 
out the total liposome concentration. Additional to that, % CF leakage was also determined 
from the equation described by Ishii et al. (15). These calculations were applied after 











3.3.5 Vesicle size and zeta-potential determination 
Mean diameters and polydispersity index (PDI) of liposomes were determined by photon 
correlation spectroscopy (PCS) by using a ZetaSizer (Nano Series; Malvern instruments 
GmbH, Germany), with a scattering angle of 90° at a temperature of 25° C. Before all the 
measurements, 10 µl liposome suspensions were diluted with bidistilled water in the ratio of 
1:6 (v/v). The zeta potentials of the particles were determined by Laser Doppler Anemometry 
(LDA) on using a ZetaSizer (Nano Series; Malvern instruments GmbH, Germany) and the 
measurements were performed in a folded electrophoresis cell with 633 nm He-Ne Laser, 
scattering angle of 173°, at 25° C. 70 µl of liposome suspension were diluted with 730 µl  
bi-distilled water and measured in triplicates. The results were expressed as mean ± standard 
deviation of mean (S.D.).  
 
3.3.6 Atomic Force Microscopy 
The stability against FCS was determined by using Atomic Force Microscopy (AFM). 
Morphology of the liposomes was observed before and after incubation in FCS by AFM 
which was performed on a JPK NanoWizard™ (Berlin, Germany). The AFM was tuned to 
provide acoustic and vibrational damping. The samples were treated with silicon cantilevers 
with ultra sharp tips (radius of the tip curvature <10 nm). The resonance frequency was kept 
at ~170 kHz, and the scan speed was proportional to the scan size. To avoid damaging of the 










3.3.7 Thermostability  
Each liposomal formulation were diluted with bi-distilled water containing 0.9 % NaCl  
(1:6 v/v) incubated for 4 hours at 25° C, 36° C, and 60° C. After incubation, the samples were 
cooled down to room temperature and the mean diameters and polydispersity index (PDI) of 
liposomes were determined by using PCS.  
 
3.3.8 Stability during Autoclavation 
The samples were autoclaved to evaluate sterilization potential. Autoclavation was performed 
on a standard autoclave 3850 ELC (Systec GmbH, Wettenberg Germany). Samples were 
diluted with bi-distilled water containing 0.9 % NaCl (1:6 v/v) and were treated with a 
standard autoclavation procedure for solutions (15 min at 121° C, 29 psi pressure and 
saturated steam). After cooling down, the mean diameters and PDI of liposomes were 
determined by using PCS as mentioned above.  
 
3.3.9 pH Stability 
To observe the pH effect on the mean diameter of the liposomes, the measurements were done 
with different pH-values mimicking the gastrointestinal environment. 100 µl aliquots of 
liposome formulations were incubated in 600 µl of various pH buffer solutions; pH 2.0 (50 ml 
of 0.2M KCl, 13 ml 0.2 M HCl), pH 4.0 (100 ml 0.1 M KHC8H4O4, 0.2 ml 0.1 M HCl), pH 
7.4 (100 ml 0.1 M KH2PO4, 78.2 ml 0.1 M NaOH), pH 9.0 (100 ml 0.1 M C4H11NO3 and 11.4 








3.3.10 Stability in lung surfactant 
The lung surfactant Alveofact was obtained from Lyomark Pharma (Oberhaching, Germany). 
The structural integrity of liposomes was measured whilst incubation with Alveofact, 
mimicking the conditions in the human respiratory system. 1 ml of total lipid solution was 
treated with 60 mg of Alveofact vial and 1ml HBS mixture (16). CF liposome solutions 
containing 50 mM CF were incubated in Alveofact solution with a ratio of 1:9 (v/v) (13). To 
determine the CF leakage due to liposome disruption induced by Alveofact incubation, the 
samples were placed into 96-well plates and fluorescence measurements were performed by 
using an excitation wavelength of 480 nm and emission was detected at 530 nm. The system 
was set for the liposomal amounts to give a total fluorescence between 3000 and 6500 
arbitrary fluorescence units (FU) at a gain of 55 FU to avoid quenching effects. (Tecan 
Saphire 2, Tecan, Austria) 
 The initial fluorescence was determined right after starting the incubation. To determine the 
total fluorescence, after 4 hours of incubation at 37° C, Triton X-100 (1.0 % v/v 
concentration) was added to the CF liposomes in the volume ratio of 1:20 to disrupt CF 
liposomes (17).  
 
3.3.11 Stability against FCS 
Resistance against FCS incubation was observed using commercial FCS. % CF leakage was 
investigated for each one of the liposome formulations. The liposome formulations were 







starting incubation, the initial values were measured. The same fluorescence settings were 
used as explained above. The % CF leakage was calculated with the equation of:  
 
 
where, Fi denotes initial fluorescence intensity, F is the intensity after 4 hours incubation in 
related mediums and Ff is the final intensity in the absence of Triton X-100 (18). The same 
calculations were repeated as before with the values of Alveofact incubation. 
 
3.4 Results  
3.4.1 Characteristics of liposomes 
Liposomes were prepared with the compositions of 0:10, 5:5, 7:3, 0:10 TEL:Ph (molar ratio). 
The mean size, zeta potential and polydispersity indexes (PDI) were compared according to 
the TEL proportion. This data is presented in Table 1. To prepare unilamellar liposomes, the 
liposome solutions were extruded for 21 times through a 100 nm extrution filter (19). 
The initial diameters of the liposomes vary from 34.5 nm to 135.6 nm. The PDI values 
were between 0.120 and 0.240, and all the liposomes were negatively charged. This negative 
charge increases with ascending tetraether lipid content. The potentials vary from -19.40 to  
-49.90 mV. With the increase of TEL proportion, the size of the unilamellar liposome 
increases as well. Initial mean diameter, PDI and zeta potential of the different formulations 
of the liposomes are listed in Table 1. % CF encapsulation efficiencies of the formulations 







for 0:10 TEL:Ph, 11.36 mM (22.73±0.21 %) for 5:5 TEL:Ph, 10.21 mM (20.43±5.71 %) for 
7:3 TEL:Ph,  10.24 mM (20.48±4.94 %) for 10:0 TEL:Ph. 
 
Table. 1.  Initial properties of liposomes were measured 1 day after preparation. Mean 
diameters (nm) and polydispersity index (PDI) of liposomes were determined by photon 
correlation spectroscopy (PCS) and the zeta potentials (mV) of the particles were determined 
by Laser Doppler Anemometry (LDA) by using a ZetaSizer. 
 
Formulation 
         Mean          
Diameter ± S.D.                                
ζ-potential  
±S.D. 
(Molar Ratio)          [nm]   PDI ± S.D.   [mV] 
                                                                                                                                                      
10:0 TEL : Phospholipon 100H     135.60±0.03                    0.160±0.03  -49.90±0.91 
7:3   TEL : Phospholipon 100H     107.00±0.53   0.120±0.02               -45.50±0.63 
5:5   TEL : Phospholipon 100H                                                       99.64±1.04   0.190±0.02  -42.50±1.41 
0:10 TEL : Phospholipon 100H     34.50±0.77   0.240±0.01  -19.40±0.03 
 
 
3.4.2 Thermostability of the liposomes 
Liposomes were incubated at different temperatures. The relative thermostability of the 
liposomes was investigated with mean size and the polydispersity index measurements after 4 
hours of incubation at various temperature conditions. At room temperature and at 36° C no 
significant difference was observed. However, at 60° C, the size of the formulation 0:10 
TEL:Ph  was found to be 149.2±1.39 nm and an increase of the PDI value could be observed 







stability at higher temperature conditions. Hydrodynamic diameters are illustrated in Figure 2 
and the PDI results after incubation are listed in Table 2.  
 
 
Figure 2. The hydrodynamic diameters of liposomes were determined after 4 hours 














Table. 2.  The PDI measurements were evaluated after 4 hours incubation in related 
temperature conditions.  
              Formulation   
                                                 
PDI ± S.D.                                                   
             (Molar Ratio) 25° C 36° C 60° C 
                                                                                                                                                      
10:0 TEL : Phospholipon 100H  0.150±0.03 0.170±0.04 0.170±0.05 
7:3   TEL : Phospholipon 100H 0.120±0.02 0.130±0.01 0.140±0.02 
5:5   TEL : Phospholipon 100H                                                0.156±0.01 0.148±0.06 0.176±0.01 
0:10  TEL : Phospholipon 100H 0.240±0.04 0.250±0.08 0.440±0.11 
 
 
3.4.3 Stability during Autoclavation 
Clinical applications of liposomal vesicles require absolute sterility. Since conventional lipids 
mostly degrade during heating or radiation, structural improvements are necessary to 
overcome this drawback are necessary (20, 21).  
As an alternative, 0.2 µm bacterial filters were also reported to have a limited scope because 
the sterilization of the liposomes with these bacterial filters is only suitable for liposomes 
smaller than 300 nm mean diameter (22). This proves to be a severe drawback for the clinical 
use of liposomes. Therefore, stability of TEL liposomes was investigated under autoclavation 
conditions according to Bode et al. (14). Previously, we have reported the autoclavation data 
for Glycerol Dialkyl Nonitol Tetraether (GDNT) liposomes (5). Due to the high stability 







formulations were compared after autoclavation. Size and PDI values were determined  
(Fig. 3). The liposome solutions were autoclaved (121° C) for 15 min. 10:0 TEL:Ph liposome 
formulations were intact and it was indicated that they have high stability even at this 
temperature. The PDI values were observed to be under 0.200 and no significant difference 
was observed between the hydrodynamic sizes of liposomes before and after autoclavation. 
The 0:10 TEL:Ph formulation was used as a negative control in this study. In the comparison 
of the hydrodynamic size and PDI values before and after autoclavation, high increase of both 
parameters was observed for this formulation.  
 
Figure 3. Stability of TEL:Ph formulations under BA: Before Autoclavation, AA: After 
Autoclavation. The measurements were conducted in triplicates. Bars represent the 
hydrodynamic diameter (nm), the line represents the PDI after autoclavation. The initial PDI 
values before autoclavation are 0.160±0.030, 0.122±0.015, 0.192±0.022, 0.236±0.014 for 









3.4.4 pH stability 
After incubation in different pH media, the effect of the TEL proportion on the liposomes was 
observed. As it was reviewed elsewhere, with increase of pH, permeability of phospholipid 
membrane increases and liposomes swell in an attempt to compensate the pH imbalance 
across the inside and outside of the membrane (23, 24). In Figure 4 it is shown that the  
0:10 TEL:Ph liposome size increases by more than 4 times of its initial size. Also mean 
diameter for this formulation was doubled. TELs provide osmotic resistance to the liposomal 
membrane by their specific chemical properties as reported previously (5). Besides, the other 
formulations with different proportions of TEL show no significant change of size and PDI 


















Figure 4. Hydrodynamic diameters were presented after 4 days of incubation in pH buffers 
mentioned in Material and Method section. For 10:0 TEL:Ph PDI varies between 0.14±0.02 to 
0.24±0.03, for 7:3 TEL:Ph between 0.06±0.05 to 0.15±0.07, for 5:5 TEL:Ph between 
0.22±0.09 to 0.14±0.02. But for 0:10 TEL:Ph at pH 9.0; 0.28±0.04, at pH 7.4 0.20±0.11, at 
pH 4.0; 0.31±0.15; at pH 2.0; 0.43±0.12 (Mean±S.D).  
 
3.4.5 Stability against Alveofact and FCS 
The same liposome formulations as mentioned above were investigated to observe the ability 
of survival in the lung surfactant. % CF encapsulation efficiency was measured right after the 
incubation as explained in Material Method section. The initial % CF encapsulation 
efficiencies of the formulations  were 18.8±3.81 % for 0:10 TEL:Ph, 22.73±0.21 % for  
5:5 TEL:Ph, 20.43±5.71 % for 7:3 TEL:Ph,  10.24 mM (20.48±4.94 %) for 10:0 TEL:Ph. 
Figure 5 illustrates the % CF leakage after 4 hours of FCS and Alveofact incubations. The 
results were 95.50±0.86 % (0:10 TEL:Ph), 96.01±0.11 % (5:5 TEL:Ph), 96.18±2.45 %  







93.91±0.48 % (5:5 TEL:Ph), 92.62±1.27 % (7:3 TEL:Ph), 89.81±0.60 % (10:0 TEL:Ph). 
Liposomes incubated in FCS and Alveofact solution showed similar leakage behaviour. With 
increasing ratio of TEL in the liposome formulations, the integrity of the liposome structures 
was preserved. After 4 hours of incubation, the release of CF was kept under 10 % for all 
formulations. Also, AFM images in Figure 6a and 6b show the comparison of liposomes 
before and after 4 hours incubation in FCS. 0:10 TEL:Ph liposomes were the least stable of all 
tested formulations and released 8.28±06 % CF during Alveofact incubation, and  
5.04±0.17 % CF during FCS incubation. After 5 hours incubation of liposomes prepared with 
Thermoplasma acidophilum lipids in various concentrations of FCS, 0 % CF leakage was 
observed. This may be evaluated as evidence that, unlike ester liposomes, ether liposomes 
have a resistance against high density lipoproteins in blood, plasma or serum because of their 
bilayer-spanning tetraether lipids (25). Concerning pulmonary delivery, this bilayer-spanning 
property of TEL also explains the resistance against Alveofact. Even though the stability 
decreases after 5 hours of incubation in Alveofact solution for all formulations in comparison 
to FCS, the % CF Leakage in Alveofact is similar to the leakage in FCS incubation. And still 














Figure 5. % CF leakage of 10:0, 7:3, 5:5, 0:10 TEL:Ph liposome formulations after 5 hours 
incubation in Alveofact and FCS.  
 
 
Figure 6. Figure A displays the AFM image of initial 7:3 TEL:Ph liposomes and Figure B 










In this study the stability properties of liposomes according to potential applications in lung 
and gastrointestinal environment have been addressed. The liposomal formulations containing 
TEL could be prepared with well-defined sizes. It was considered that liposomes with more 
than 90 % of bipolar tetraetherlipids of total polar lipid extracted from  
Thermoplasma acidophilum are more stable than diester/diether lipid liposomes (4). This 
approach proves that the TEL molar ratio has a distinctive effect on stability against various 
pH and temperature conditions, biological environments (FCS and surfactant) and 
autoclavation. 
It is reported that the permeability of tetraether lipid liposomes is less sensitive to temperature 
changes (26). In our study, mean diameters of all liposome formulations were measured and 
found to be below 0.2 µm and tetraether lipid fraction exhibits large negative zeta potential in 
agreement to Komatsu et al. (27); as the temperature increases to 60
o 
C, the size of liposomes 
formed with pure Phospholipon 100H increases too. These results show that TEL liposomes 
are less temperature-sensitive than phospholipon containing liposomes, which was reported to 
be the result of membrane permeability and viscosity properties of the extracted membrane 
lipids (28). The PDI values for each composition under different temperatures indicate similar 
stability behaviour except for the liposomes consisting of pure Phospholipon. 
Benvegnu et al. have also shown that the addition of synthetic TEL to conventional liposomes 
increases their stability (3). This study shows that the diameters of liposomes are highly stable 
at different pH values if sufficient amount of TEL is added to the formulation. At very low pH 







reported that liposomes prepared from tetraether lipid mixtures offer much lower proton 
permeability (19). This unique property is an adaptation of the archaea cell membrane to 
extreme environmental conditions, in order to maintain the intracellular pH of the cell. The 
results shown in Figure 4 can be explained with the liposome membrane integrity at low pH, 
provided by the lipid backbone, orientation of tetraether lipids and also by bi-polar head 
groups in their structures. Although Thermoplasma acidophilum grows optimally at pH 2, it 
has an internal pH of 6.9 (29, 30). To cope with this huge pH difference,  
Thermoplasma acidophilum has developed cytoplasmic membrane lipids which consist of 
asymmetrical, negatively-charged phosphate headgroups (31, 32). Therefore, with increasing 
TEL component of the liposome formulation, proton permeability decreases resulting in 
increased pH stability.  
It is indicated that that TEL enables liposomes to be sterilized via autoclavation. Especially 
the pure TEL formulation showed no significant change after autoclavation in regard to size 
and PDI. As the Phospholipon concentration exceeds 50 %, stability starts to decrease 
gradually with an increasing PDI value. Stamm et al. have shown the potential of sterilization 
by filtration of liposomes through 0.2 µm filters and in this study we have presented a more 
reliable sterilization method (33). 
The TEL proportion seemed to have a certain stabilising effect under serum and lung 
surfactant incubation. Patel et al. pointed out that low % leakage of CF occurred in TEL 
liposomes during the incubation in fetal calf serum albumin because of vesicle disruption 
rather than increasing permeability. (34). In contrast, the AFM image of liposomes after  
5 hours of FCS incubation (Figure 6B) shows well-shaped particles; however, low % CF 








The % CF leakage results presented in  Figure 5 are in good agreement with Choquet et al. 
(Tetraether lipid liposomes from Thermoplasma acidophilum showed 0 % CF leakage in  
20 %, 50 % and 100 % serum concentrations) (28).  
The % leakage of CF in different compositions both in Alveofact and FCS indicates that TEL 























Our study demonstrates that TELs enhance the stability of liposomes, especially if they 
represent more than 50 % of the formulation. Since the TELs are adapted to very high 
temperatures, sterilization of liposomes by autoclavation is possible and provides considerable 
advantages for clinical applications. Significant stability with only slight variations in size, 
PDI and retention in serum and lung surfactant were observed. Thus, these liposomes offer 
attractive possibilities for treatment applications aiming at the pulmonary system and the 
gastrointestinal tract.  
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4.1  Abstract  
For the development of site specific liposomes, high stability and long circulation properties 
are very promising for the improvement of drug targeting and drug delivery system as well as 
improvement of bioavailability of efficient bioactive drugs. Tetraether lipids (TELs) are very 
stabile lipids, extracted from Thermoplasma acidophilum.  Because of its high chemical 
stability and its biocompatibility, Tetraether lipid liposomes prepared with TELs are excellent 
candidates for liposomal drug delivery. In this study a model protein, Concanavalin A (ConA) 
was chosen for a simulation of a specific adsorbtion onto mannan surface. Concanavalin A 
(ConA) is a lectin, extracted from Canavalia ensiformis, which interacts with sugar domains 
localized on inflammatory active tissues or tumors.  In this study, stable TEL liposomes were 
prepared and characterized.  Furthermore to develop side  specific liposomes, tetraether lipids 
were activated and, ConA was covalently bond onto the surface of the prepared liposomes. 
Interaction of ConA conjugated liposomes with mannan-modified surfaces was investigated 
by Biomolecular Interaction Analysis (BIA) via Reflectometric Interference Spectroscopy 
(RIfS). This provides real time observation of interactions between carbohydrate structure and 
TEL liposomes. Specific interaction was also visualised by AFM imaging subsequent to the 
RIfS measurements. According to the results, with ConA conjugated liposomes, high specific 
adsorption efficiency was observed. Consequently, this specific adsorption assay between 
ConA and mannan surface can be considered as a model for the further studies utilized with 












In the past several decades, the progress in the field of liposomal technology has shown 
promising results with respect to minimization of side effects of pharmaceuticals due to 
longer circulation of liposomal formulations and tumor specific targeting. However, stability 
of liposome is of great concern. In contrast to many other conventional liposomes, Tetraether 
lipid (TEL) liposomes prepared with highly stable TEL possess extended circulation 
properties. TELs can be isolated from thermoacidophilic archaeon  
Thermoplasma acidophilum (1). Thermoplasma acidophilum is able to survive in extreme 
external condition of pH 2 and at temperatures up to 59° C because of very stable chemical 
structure of their membrane lipids. Unlike most bacterial membrane lipids, Archeal membrane 
lipids include pentacycles in hydrocarbon chains and ether bonds instead of esters. TEL does 
not have any double bonds in its chemical structure which causes a superior stability to TEL 
liposomes under harsh conditions (2). Because of these properties, they are rather promising 
for therapeutical applications. 
In a model investigation, interactions between lectin and carbohydrates present on inflamed 
tissue were intensively investigated (3). The lectin-carbohydrate interaction mediated 
leukocyte rolling throughout the vascular surface to provide inflammation-response inspired 
leukocyte targeting. This interaction was also utilized in site-specific drug delivery in cancer 
therapy to reduce side effects of the drugs (4). Effective targeting of a drug carrier towards 
tumor tissue provides efficient therapy with low amounts of drug and low side effects (see 
Figure 1).  
Hence as a model marker, the first commercially available lectin, Concanavalin A (ConA) 







ensiformis. It contains two metal binding sites, which bind to sugar domains localized on 
inflammatory active tissues or tumors (5-7). This model receptor was covalently bound to 
outer surface of bilayer membrane of liposomes. This interaction provides aspects for further 
studies with the use of specific biomarkers.  
In this study specific interaction of ConA modified liposomes with mannan surface were 
investigated by Biomolecular Interaction Analysis (BIA) via Reflectometric Interference 
Spectroscopy (RIfS) and Atomic Force Microscopy (AFM).  RIfS was previously described 












Figure 1. Molecular structure of the tetraether lipid A.) cyanuric chloride activated TEL and 
B.) activated TEL conjugated with ConA, C.) AFM image (height) of the TEL:DPPC:ConA-














4.3 Experimental  
4.3.1 Chemicals 
Tetraether lipids were a kind gift of SIT GmbH and Interfeace Technologies 
(Rosenhof/Heiligen Stadt, Germany). L-Alpha-dipalmitoyl phosphatidylcholine (DPPC) was 
obtained from Acros Organics (USA). ConA was obtained from Vector Laboratories (USA). 
Chloroform and methanol were both HPLC grade and purchased from Fischer Scientific 
(UK). Cyanuric chloride, sodium hydroxide, sulphuric acid, hydrogen peroxide, sodium-
tetraborate decahydrate, 1.4 butanediol diglycidyl ether and mannan were purchased from 
Sigma Aldrich (USA). Sodium borohydride obtained from Fluka (Germany) and 3-
aminopropyl-triethoxysilane was purchased from Sigma Aldrich (China). All chemicals were 
of analytical grade. 
 
4.3.2 Instruments 
Reflectometric Interference Spectroscopic (RIfS) measurements were performed with a 
BIAffinity device from Analytik Jena AG (Jena, Germany). The bio-chips necessary for BIA 
measurements were a kind gift of Analytik Jena AG (Jena, Germany). AFM imaging was 
performed with a JPK NanoWizard™ (sensor measurements JPK Instruments, Berlin, 
Germany) equipped with silicon cantilevers NSC 16 AlBS, Micromasch (Estonia) and a 
Bioscope Nanoscope IV (liposome visualisation, Veeco Instruments, Mannheim Germany). 










4.3.3 Preparation of non-activated tetraether lipid liposomes 
TEL was extracted from biomass of Thermoplasma acidophilum in the presence of 
chloroform:methanol (2:1 v/v) (12-14). TEL was mixed with DPPC in the concentration of 1 
mg/ml (70:30 molar ratio) and dried under vacuum at 50° C in round bottomed flask in order 
to obtain a thin lipid film. The film was hydrated with PBS buffer pH 7.4 containing 0.1 M 
NaCl. To achieve a clear dispersion, the sample was exposed to ultrasound treatment with a 
tip-type sonicator for 8 min. (30 sec sonication followed by 30 sec rest).  After sonication, the 
sample was filtered and extruded through a 0.1 µm polycarbonate membrane. Before BIA 
analysis, the sample was diluted with PBS buffer in 1/30 ratio. 
 
Table 1: Size and zeta potential were measured by PCS (Photon Correlation Spectroscopy), 
AFM, and zeta potential. TEL:DPPC:CyCl-TEL are the activated TEL liposomes and 








4.3.4 Preparation of Concanavalin A-modified TEL liposomes 
Tetraether lipids from biomass of Thermoplasma acidophilum were extracted in the presence 
of chloroform:methanol (2:1 v/v) as described above (12). After extraction, organic solution 
was removed by drying of the sample under vacuum at 50°C to prevent the oxidative effect of 
methanol on activated TEL (CyCl-TEL). For preparation of TEL:DPPC:CyCl-TEL (65:30:5 
molar ratio), initially activated TEL (CyCl-TEL) was prepared, by mixing of TEL with 
cyanuric chloride (2:1 molar ratio) in the presence of chloroform according to the method 
previously reported. (6). The mixture was stirred at Room Temperature (RT) overnight to 
provide the one side activated TEL. CyCl-TEL was mixed with TEL and DPPC in the molar 
ratio of 70:30 and in the concentration of 1 mg/ml, and dried under vacuum at 50° C in a 
round bottomed flask to obtain a thin lipid film. The final preparation process was continued 
similarly to the non-activated TEL:DPPC liposomes. The film was hydrated with PBS buffer 
pH 7.4 containing 0.1 M NaCl. A clear dispersion was obtained by ultrasound treatment as 
described above.  After sonication, the sample was filtered and extruded through a 0.1 µm 
polycarbonate membrane. As the non-activated liposomes, the obtained liposomes had a 
diameter between 100-200 nm with a polydispersity index (PDI) of 0.1-0.2 and zeta potential 
between – 11 and –18 mV (see Table 1). 100 µl aliquot of the prepared sample was added to 
2.9 ml borate buffer pH 8.8 containing 0.1 mM MnCl2 and CaCl2 (15). For lectin ConA was 
added (1:1000 protein:lipid ratio) into this mixture and stirred at RT overnight (16). Samples 











4.3.5 Bio-chip design 
Mannan coated bio-chips were prepared by covalent binding of mannan molecules according 
to a modified method previously reported by Hartmann et al. (17). A glass chip (1.3x1.3 cm, 
100 µm thickness) was activated by incubation of 2 min with 6 M sodium hydroxide solution, 
and activated with piranha solution (H2SO4 96 % H2O2 30 % (v/v) 60:40) for 30 min. Amino-
functionalization was done with 3-aminopropyl-triethoxysilane (APTS).  Chips were 
incubated in 1 % (v/v) APTS in toluene for an hour and then washed with toluene to remove 
the loosely physisorbed APTS. Then, the chips were incubated at 105° C for an hour. 
Afterwards, bio-chips were immersed into 0.2 M sodium-tetraborate decahydrate buffer (pH 
10.0) containing 1.4 butanediol diglycidyl ether (3 ml/10 ml buffer) and sodium borohydride 
(6 mg/ml buffer) for 12 h. Finally, 5 mg/ml mannan was dissolved in this buffer and glass 
chips were immersed and incubated in this solution for 24 h at RT. Before RIfS 
measurements, bio-chips were rinsed with Millipore
®
 water and dried. 
 
4.3.6 RIfS measurements 
Interactions between the prepared chip and ConA were performed in accordance to Hartmann 
et al. and by Nikitin et al.  (17,18). The real time interaction was observed by the BIAffinity 
device. Interactions of ConA modified liposomes and non-modified (plain) liposomes with 
the mannan coated chip were investigated. BIA was performed at RT within PBS buffer 
solution pH 7.4 including a washing step of about 2,100 sec for ConA conjugated liposomes 
and of about 1,700 sec for non activated liposomes over an interaction time of 3,050 sec. For 







analysis, it was possible to observe a clear differentiation of ConA modified liposomes and 
non-activated liposomes interactions onto sugar coated surface. Related results were discussed 
in section 3.1. 
  
4.3.7 AFM measurements 
The activation of liposomes with ConA was also confirmed by AFM. After RIfS 
measurements of specific interaction between both ConA modified liposomes and unmodified 
liposomes and the mannan coated bio-chips, the coverage of bio-chip surfaces with the 
liposomes was investigated by imaging the surface with AFM. For this purpose, the chips 
were removed from the RIfS device and then washed with Millipore
®
 water and dried in air 
flow. AFM imaging was performed on a JPK NanoWizard™ and a Bioscope Nanoscope IV. 
Silicon cantilevers with ultra sharp tips (radius of the tip curvature <10 nm), resonance 
frequency ~170 kHz and a nominal force constant of ~40 N/m were used. To avoid damaging 
of the surfaces, intermittent contact (air) mode and Tapping mode™ were chosen. The scan 
speeds were proportional to the scan sizes. ImageJ software was used to calculate surface 
coverage with ConA modified and unmodified liposomes from 10 x 10 µm AFM images. 
Surface coverage was calculated as percentage of surface covered with liposomes divided by 













4.4 Results and Discussions 
4.4.1 RIfS analysis of ConA interactions 
The interaction between the TEL:DPPC liposomes, which were functionalized with the lectin 
ConA, were investigated by Reflectometric Interference Spectroscopic (RIfS) measurements. 
The interactions between liposomes and mannan surface are illustrated in Figure 3D).  
Mannan coated chips were used to screen the difference in the attachments of unmodified 
TEL:DPPC liposomes in comparison with TEL:DPPC liposomes surface modified with 
ConA.  After injection of unmodified liposomes into RIfS device (control measurement), a 
negligible number of liposomes was able to adhere to the mannan surface due to the 
unspecific interaction (Figure 2). In conrast; adhesion was relatively high for ConA 
conjugated liposomes. After equilibrium in order to designate the specific specific adsorption 
of liposomes onto mannan surface, a standard buffer washing application was administered. 
As easily visible, bounded liposomes could be nearly completely removed indicating that 
these liposomes were bound to the surface in an unspecific manner. It was observed that the 
signal of unmodified TEL:DPPC liposomes decreased up to 44 %, however for modified 
liposomes this value was only 14 % After the washing step, a nearly constant signal followed. 
Representative sensograms are shown in Figure 2. Association and dissociation phases are 
clearly visible for loaded and unloaded liposomes. The adsorption behaviour of TEL 
liposomes was characterized by calculation of dissociation rate constant (KD). KD 
=kdiss/kass. Kass is association rate constant and kdiss is dissociation rate constant. The KD 











 and the KD value was 2.70×10
−8













Figure 2. Reflectometric Interference Spectroscopic (RIfS) measurements: A.) liposomes 
conjugated with ConA, which were added to a mannan-coated surface. B.) control channel 
with plain liposomes. After 400 sec, liposomes were added (association). After 1,700 sec, 










4.4.2 Investigation of ConA interactions with AFM 
Additionally to RIfS investigations, interaction of ConA conjugated TEL was also 
investigated by means of AFM. After each measurement of adsorption with BIA, bio-chips 
were removed and rinsed with Millipore
®
 water and investigated by AFM by using tapping 
mode. Figure 3 a,b,c indicate the difference between non-activated and without ConA 
conjugated TEL and ConA conjugated TEL (ConA-TEL). TEL:DPPC liposomes were 
attached onto the surface of a mannan coated bio-chip, when liposomes were conjugated with 
ConA. In contrast, non-activated TEL liposomes were attached only in small amount onto 
mannan surface in an unspecific manner. Figure 3A illustrates the mannan coated surface. 
Specific interactions between modified liposomes are illustrated in Figure 3C. Figure 3B 
shows the control experiment with unmodified liposomes. These results clearly show that the 
mannan surface only shows little unspecific interactions. The AFM images were evaluated via 
the software ImageJ in order to compare the relative surface coverage properties. The result 
showed that ConA conjugated liposomes provided 5.68 ± 0.02 % surface coverage on the 
other hand this value was only 0.57 ± 0.07 % for unmodified liposomes. Remarkable 
similarity with RIfS measurements ensured the specific adsorption of ConA modified 













Figure 3. Schematic of the mannan modified sensor surface and the attachement of ConA 
conjugated liposomes. AFM images of A.) mannan coated glass chip, B.) attachment of 
TEL:DPPC (70:30 molar ratio) liposomes onto mannan coated glass chip  C.) attachment of 
ConA-modified liposomes (TEL:DPPC:ConA-TEL), 65:30:5 molar ratio) onto mannan 
coated glass chip. Each bar represents 1µm. D.) The sketch shows the adhesion of ConA 










Tetraether lipids have unique stability properties because of their chemical structures. Unlike 
conventional lipids, they are attached to glycerol backbone via ether bonds. Tetraether lipids 
have saturated carbon bonds which provide high oxidation resistance (22).  Due to these 
chemical properties high stability under extreme conditions such as low pH values (23) or 
high temperatures (24) can be acheived. Because of enhanced structural stability and 
eligibility of various protein modifications tetraether lipids are atractive as side-specific 
targeting agents in many biotechnological applications.  
Until now various phospholipid ConA interactions were studied (25). In this study particularly 
TEL liposomes were used to prepare specific liposomes in order to specifically target tumors 
or inflammatory active tissues. These site specific liposomes minimize the side effects of the 
therapeutic drugs. Therefore, in this study TEL liposomes with highly stabile lipids were 
prepared and characterized.  The ConA conjugations of TEL liposomes serve as a drug 
targeting model for the future studies. This adsorption model based on mannan coated chips 
was established in order to provide screening of modified and unmodified TEL liposomes 
according to their adsorption properties. RIfS measurements in combination with AFM 
measurements provide information about the interactions characteristics of liposomes in a 
wide range. ConA shows high affinity to the mannan and this adsorption behaviour was 
already discussed by Goldstein et al. (26).  
The present study might provide an important aspect to determine interactions of other lectins. 
Lectin conjugated TEL liposomes are promising for drug targeting systems to be used as 
specific therapy with low amount of drug and low side effects with  regard to drug targeting 
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5 Imatinib Encapsulated Tetreaether Lipid Liposomes 










5.1  Abstract  
Extremely stable tetraether lipids isolated from Thermoplasma acidophilum were used for 
encapsulation of tyrosine kinase inhibitor Imatinib (Glivec
®
- STI 571). Imatinib inhibits the 
BCR-ABL, KIT, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases. 
Imatinib containing TEL liposomes were examined for their anti-angiogenesis effect in a 
CAM assay. The Chorioallantoic Membrane (CAM) assay is very appropriate for both 
angiogenesis and anti-angiogenesis studies because of a very dense capillary network, low 
cost and eligibility of continuous microscopic visualization and screening of the implants and 
tissue reactions. The gelatine sponges were absorbed with MB49 (the mouse urothelial 
carcinoma) cell suspension. These sponges were placed onto the CAM and treated with 
imatinib containing TEL:DPPC liposomes, whereafter gradual deformation in vascularisation 
on CAM was clearly detectible. Moreover, it was shown that upon encapsulation in liposomes 
a lower concentration of imatinib was needed to suppress the enhanced phosphorilation of 

















Since 1970 liposomes have become very attractive as pharmaceutical carriers of great 
potential. Liposomes are already being used as industrial products for clinical applications 
because of many attractive biological properties such as biocompatibility, both hydrophilic 
and hydrophobic pharmaceutical incorporation capability, as well as efficient delivery into 
cells and even into individual cellular compartments (1). Doxil
®
 Liposomal doxorubicin was 
the first liposomal chemotherapy product to be approved in US (2).  Since then the application 
of liposomal drug delivery systems has achieved considerable success for the treatment of 
solid tumors in patients, and is promising for further investigations (3). However, liposomal 
drug carriers prepared from conventional phospholipids exhibit several drawbacks, especially 
considering stability (4).  
To overcome these stability drawbacks, very stable lipids from Thermoplasma acidophilum 
were used for the preparation of liposomes in this study. The thermoacidophilic archaeon 
Thermoplasma acidophilum was isolated and described by Darland et al. (5). The suitable 
living conditions of this archaeon are around pH 2 and 56° C. Resistance against these 
extreme environmental conditions is gained through unique chemical and physical properties 
of core membrane lipids of archaeal bilayer membranes. Bipolar tetraether lipids consist of 
saturated chains with methyl branches attached to the ether bonds instead of ester bonds. 
These properties are also discussed in depth by Jacquement et. al., Freisleben et al., 
Bakowsky et al., Hanford et al. (6-9). The chemical and physical properties of tetraether 
lipids provide improved stability to the liposomes allowing a larger spectrum of application 
(10). In this article we have addressed the encapsulation of a water soluble protein-tyrosine 
kinase inhibitor „Imatinib‖ (Glivec
®









) inhibits the BCR-ABL, c-KIT and platelet-derived growth 
factor receptor (PDGFR) tyrosine kinases (11-13). In cancer and benign proliferative 
disorders, protein-tyrosine kinases play a fundamental role in signal transduction. Foreign 
substances like imatinib can affect the tyrosine kinase signal cascade (14). After Phase III 
trials, Imatinib was approved for first-line treatment of chronic myeloid leukemia and 
malignant gastrointestinal stromal tumors (GIST) (15, 16). It has been stated that the use of 
Imatinib could also induce antiangiogenic and/or antivascular effects in GIST (17). This 
antiangiogenic effect is mediated by the platelet-derived growth factor receptor (PDGFR) 
(18). Prevention of angiogenesis is anticipated to suppress tumor progression. In our study we 
have addressed stable liposomal nano-particles which encapsulated Imatinib (STI 571) for the 
approach of anti-angiogenesis as a novel anti-cancer strategy (19-21).  
To provide a different perspective on investigation of anti-angiogenesis effect of Imatinib 
with and without liposomal encapsulation, a chorioallantoic membrane (CAM) assay was 
performed. Until the development of the CAM assay, several other angiogenesis assays were 
performed, among them rabbit ear chamber, rodent eye cornea, hamster check pouch and 
cornea, rodent dorsal skin and air sac. In practice these assays appeared to be complicated to 
apply, unsuitable for high quantity of test compounds, expensive and in most cases required 
specific surgical skills (22, 23). CAM is an extraembryonic membrane of a developing chick 
embryo; it is very attractive for angiogenesis and anti-angiogenesis studies because of its very 
dense capillary network, easy and rapid methodology, low cost and no sterility requirement. 
Also the immune system of the chick is not fully developed during the embryo stage, meaning 
the rejection system is not yet exerted. Besides these advantages, the CAM assay is 
preferential for angiogenesis and anti-angiogenesis studies because of its suitability for testing 
high quantities of various compounds (23-25). Furthermore, the CAM assay allows 







(26). During the CAM assay, the chick embryo may be removed from the egg shell (ex ovo) to 
provide large screening techniques. Because of several limitations such as low embryo 
survival rate, difficult methodology and no possibility to properly reflect the physiological 
conditions, we performed the traditional shell model (in ovo) as described by  
Knighton et. al. (27). Drug administration onto the tumor implants on the CAM was 
performed with the use of topical, intraperitoneal and intravenous delivery methods. Unlike 
topical, the other methods can result in lower survival rate, as well as lowering of the actual 
concentration of the drug during blood circulation (28). Topical administration of liposomes 
on CAM has been investigated elsewhere for efficiency of drugs and liposomal encapsulated 
drugs (29-31).  
In this study we have not only investigated the anti-angiogenic effect of the topical 
application of a tyrosine kinase inhibitor but also the anti-angiogenic effect of a tyrosine 
kinase inhibitor encapsulated in very stable liposomes. These liposomes were tailored with 
tetraether lipids besides conventional lipid fractions. Furthermore, we implanted MB49 (the 
mouse urothelial carcinoma) as a model cell line onto the CAM and we investigated the 

















5.3 Materials and Methods 
5.3.1 Extraction of Tetraether lipids 
Tetraether lipids (TEL) were extracted from freeze-dried Thermaplasma acidophilum 
according to modified method Bode et al. (31). Thermaplasma acidophilum biomass was a 
kind gift from SIT GmbH and Interference Technologies (Rosenhof/Heiligenstadt, Germany).  
10 g biomass was refluxed at 60° C for 12 hours in presence of 500 ml CHCl3:MeOH  
(2:1, v/v) (Fischer Scientific, Loughborough, UK; Carl Roth, Karlsruhe, Germany (both 
HPLC Grade). After cooling down, the mixture was filtered through 300 g 0.02-0.045 mm 
silica 60 gel (Merck, Darmstadt, Germany). The collected brown lipid solvent was adjusted to 
10 mg/ml concentration in CHCl3: MeOH (2:1 v/v) and this stock solution was kept at -20° C 
until the preparation of liposomes. 
 
5.3.2 Preparation of tyrosine kinase inhibitor encapsulated TEL liposome formulations 
For the preparation of blank liposomes, 2 ml aliquots of extracted TEL and DPPC mixtures in 
a molar ratio of 7:3 with the concentration of 1 mg/ml were transferred into a round bottom 
flask and evaporated at 45° C and 300 mbar with rotation (Heidolph, Laborota 400, 
Schwabach, Germany) to obtain a TEL:DPPC lipid film, according to the method we have 
reported previously (10). This molar ratio was chosen to provide sufficient stability to the 
liposomes in the circulation but not to prevent the cellular lysosome (10) The lipid film was 
hydrated with 2 ml PBS containing 0.5 M NaCl and for homogenization, the solution was 
sonicated by probe type sonication for 8 minutes at a level of 6 from 10 of intensity (30 sec 







Schwöbosch, Germany). Afterwards filtration through 0.45 µm filter and 21 times of 
extrusion through 0.2 µm polycarbonate membrane filters (Avanti, Otto Nordwald GmbH, 
Hamburg, Germany) followed subsequently. During the preparation of imatinib encapsulated 
liposomes, another 2 ml aliquot was prepared as described above and the lipid film was 
hydrated with imatinib solution in a 2:1 Lipid:Drug molar ratio prepared in PBS containing 
0.5 M NaCl  (32). The same procedure for the preparation of imatinib encapsulated liposomes 
was repeated as explained above for blank liposomes. The formulations are listed in Table 1 
























Table 1. Imatinib encapsulated TEL:DPPC liposome formulations. 
Abbreviation Liposome  
Imatinib 





















Table 2. Free imatinib Solutions for topical applications 
Abbreviation Liposome  Imatinib  
























5.3.3 Size and PDI Determination of Liposomes 
The mean diameter and the polydispersity index (PDI) of the vesicles were determined by 
photon correlation spectroscopy (PCS) (Malvern instruments GmbH, Germany) with a 
scattering angle 90° C at 25° C temperature. During the size measurements a 10 µl liposome 









5.3.4 Determination of encapsulation efficiency 
According to the modified procedures of Papahadjopoulos and Fishman et al., after 
preparation  of  imatinib encapsulated TEL:DPPC liposomes, the 0.5 ml aliquots of the 
vesicle suspension were transferred into small dialysis bags with MWCO 14000 (Carl Roth 
GmbH, Karlsruhe, Germany) which were pre-EDTA-washed according to the manufacturer 
instructions  (33, 34). After 4 h dialysis of free imatinib in 500 ml buffer containing 0.5 M 
NaCl at RT, the aliquots were transferred into individual Eppendorf tubes. Total amount of 
the entrapped Imatinib was calculated after terminal lysis of the liposomes with Tween 20 
(1.0 vol % final concentration) (35). To minimize the absorption of the detergent, for the 
absorbance measurements of drug content, Tween 20 was chosen. 1.0 vol % final 
concentration of Tween 20 was mixed with the vesicle suspensions and stirred in order to 
release the encapsulated drug to the solvent.  Encapsulation efficiency was calculated 
according to Ishii et al. (36).  
 
Concentrations of the drug Cout and Ctotal were quantitatively analyzed by spectrophotometer 
(UV Mini 1240, Shimadzu, Suzhou instruments Manufacturing Co. Ltd. Suzhou Jiangsu, 











5.3.5 AFM Measurements 
Topographic investigations of imatinib encapsulated liposomes were done with Atomic Force 
Microscopy. Blank and imatinib encapsulated liposomes were separately dropped onto a 
sample carrier glass and dried in air flow and AFM imaging was performed afterwards. The 
imagining was carried out with JPK NanoWizard
TM
 (JPK Instruments, Berlin, Germany) 
equipped with silicon cantilevers NSC 16 AIBS, (Mikromasch, Estonia) with intermittent 
contact (air) mode. During the imaging, silicon cantilevers with ultra sharp tips were used 
(radius of the tip curvature <10 nm, resonance frequency ~170 kHz and nominal force 
constant of ~40 N/m). The scan speeds were proportional to the scan size, and the collected 
images were 5 x 5 µm. 
 
5.3.6 Cell Lines 
Murine Urothelial Carcinoma cell line MB49 (kind gift from Dr. Ulrich Rothe) cultured in 
Iscove's Modified Dulbecco's Media (IMDM) medium (PAA, Coelbe, Germany) containing 
10 % fetal calf serum (FCS) (PAA, Coelbe, Germany) and 1:100 (v/v) Penicillin, 
Streptomycin mixture. Until implantation, cells were incubated at 37° C with 5 % CO2. 
 
5.3.7 WST-1 Viability Assay 
WST-1 Assay was performed on imatinib and imatinib encapsulated TEL liposomes 
according to Mueller et al. (37). 5000 MB49 cells/well (Murine Urothelial Carcinoma cell 







day, the medium was changed to IMDM + 0.5 % FCS and incubation continued for 2-4 h at 
36.5° C and 5 % CO2 before treatment. The cells were incubated with various imatinib 
concentrations of free imatinib solution and imatinib encapsulated TEL solution. The imatinib 
























 µM. To determinate cell viabilities 
after 24 hours, the cells were incubated in WST-1 reagent (2-(4-iodophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)
2
 [H] tetrazolium monosodium salt) (Roche, Mannheim 
Germany), and after 30 minutes the cell viability was assessed according to the manufacturers 
recommendations and detected by an ELISA micro plate reader at 450 nm, with a 75 W 
Tungsten halogen lamp light source (Dynatech Laboratories inc. MRX Chantilly, VA, USA). 
To determine the cell viability after 48 hours, incubation in WST-1 reagent and cell viability 
detection by the ELISA reader were repeated as explained above. All formulations used for 
this assay were tested in triplicates and average values were plotted against applied 
concentrations and presented as sigmoidal curves with OriginPro 8.0 SRO (OriginLab 
Corporation, USA). The 50 % growth-inhibitory concentration IC50 was calculated from 
interpolations of the graphical data (Mean ± S.E.M). 
 
5.3.8 CAM Assay 
Fertilized VALO-SPF eggs were obtained from Lohmann Tierzucht GmbH (Cuxhaven, 
Germany) and incubated at 37.5° C und with 60 % relative humidity. On the 5
th
 day of 
incubation approximately 6-7 ml albumin was removed from the fertilized egg to detach the 
shell from the CAM, as the first described traditional shell model by Knighton et al. (27). 







2.5 cm in diameter. To prevent dehydration, the opened shell was sealed with Parafilm
®
 and 
incubated in under the conditions mentioned above until implantation. On the 10
th
 day sterile 
gelatin sponges, Gelfoam (Pfizer, Pharmacia & Upjohn Company Kalamazoo, USA) were cut 
in pieces of approximately 2 mm
3
 size and absorbed with 10 µl of cell suspension 
(approximately 30 000 cell per sponge) of MB49 cell line.  Also as negative control group,  
2 mm
3 
sterile sponges were absorbed with 10 µl of PBS. The sponges were planted gently 
onto the CAM, to a region where the vessel density was high (38). The egg was sealed again 
with parafilm and incubated until the 18
th
 day at standard conditions as mentioned above. 
Daily observations were carried out with a Stereomicroscope (Olympus SZX12, Japan) 
connected to a Moticam 2000 digital camera (Motic China Group, China). Each image was 
captured using the software of Motic Images Plus 2.0 ML (China). On the 18
th
 day, tumor 
samples were cut from CAM, transferred into individual Eppendorf tubes, quickly immersed 
into liquid nitrogen and stored at -80° C until investigation with Western Blot Analysis. 
 
5.3.9 Western Blot 
The tumors cut out from CAM were collected in RIPA lysis buffer (50 mM Tris–HCl, 1 % 
Nonidet P-40, 150 mM NaCl, 1 mM EDTA,) with 1:20 (v/v) protease (Roche, Mannheim, 
Germany) and 1:100 (v/v) phosphatase inhibitors (Sigma, Missouri, USA) and homogenised 
and centrifuged at 2500 rpm for 10 min. at 4° C subsequently. Protein concentration of the 
supernatant was determined by Bradford protein assay (39, 40). After denaturation at 95° C  
the proteins for Extracellular signal-regulated kinases 1/2 (ERK 1/2) (20 µg/lane) and for p-
ERK (30 µg/lane) into separate gels were loaded into each lane of a 10 lane gel and were size 
fractionated by 10 % SDS–polyacrylamide gel electrophoresis (Invitrogen, Paisley, UK) and 







proteins was detected by using rabbit primary antibodies, p42/44 MAPK (ERK) and phospho-
p24/44 MAPK (p-ERK) (Cell Signalling, Danvers, USA) and an anti-rabbit secondary 
antibody HRP (GE Healthcare Buckinghamshire, UK) at a dilution of 1:1000 for ERK 1/2 and 
1:500 for p-ERK 1/2. Visualization of antibody binding was done by enhanced 
chemoluminescence (Thermo Scientific, Rockford, USA). To determine the suppression of 
the protein from the implant samples on the photographic film, the imageJ program (National 
Institutes of Health, USA) was used. 
 
5.3.10 Statistics 
All values are expressed as mean ± standard error of mean (S.E.M). The results of CAM 
model assays were analyzed by Student’s T-Test to determine significant differences in 
multiple comparisons using SigmaPlot 12.0 (Systat Software, USA). All experiments were 



















5.4 Results  
5.4.1 Mean sizes and polydispersity index of tyrosine kinase inhibitor encapsulated 
TEL liposome formulations 
Unilammelar TEL:DPPC liposomes were generated by pressure extrusion through  0.1 µm 
polycarbonate membrane filters. The mean diameter for blank TEL:DPPC liposomes were 
determined as 235.30±2.63 nm with a PDI value of 0.241±0.005. On the other hand the mean 
diameter of imatinib encapsulated TEL:DPPC liposomes were shifted to 248.83±5.78 nm and 
PDI to 0.290±0.010.  
 
5.4.2 Encapsulation efficiency 
 
Percent encapsulation efficiency (EE %) was determined as a ratio of imatinib portion 
remaining inside of the TEL:DPPC liposomes to the amount of total imatinib after filtration 
and before dialysis, because loss of liposomes was observed during the filtration. To avoid 
errors, only the lipid amount which contributed to encapsulation was taken into account for 
the efficiency calculation which was carried on as it was described in the material and 
methods section. At pH 7.4 EE % of TEL:DPPC liposomes were 86,36 ± 0.88 %. Initial 
imatinib used for encapsulation was 2.88x10
-1 
mM. After filtration and liposome formation, 
the total encapsulated imatinib amount inside the liposomes was 3.43±0.14 µM. 













AFM images of TEL:DPPC liposomes with and without entrapped imatinib are shown in 
Figure 1A and 1B. Both of the formulations showed homogenous and well-defined contours 
surfaces. Incorporation of imatinib into liposomes resulted in larger vesicles size (Figure 1B).  
The diameter of these vesicles was between 250-300 nm. This indicated that the interaction 
between the drug and liposomes involved the size increase in which more liposomes tend to 
associate. This property of imatinib with DPPC lipids interactions was reported by  





















5.4.4 WST-1 Viability Assay 
We investigated the viability of blank TEL:DPPC liposomes, imatinib encapsulated 
TEL:DPPC liposomes and also free imatinib by utilizing a cell proliferation kit containing 
WST-1. Figure 2A and 2B demonstrate the cell viability after 24 hours incubation  
(36° C 5 % CO2). At A450 plateaus were determined for blank TEL, imatinib encapsulated 
TEL and non-encapsulated TEL.  With the % cell viabilities, the IC50 values for imatinib at  
24 hr and 48 hr were calculated. IC50 imatinib after 24 hr: 9.68x10
-2
 mM; IC50 of imatinib 
after 48 hr: 3.12x10
-2
 mM; and IC50 of TEL: DPPC liposome after 24 hr: 3.67x10
-1
 µM, IC50 
of TEL: DPPC liposome after 48 hr: 3.14x10
-1
 µM. To define the effect of TEL: DPPC (7:3) 
blank liposome, WST-1 assay was repeated for this formulation as well. The blank liposomes 



































Figure 2. A WST-1 assay was used to quantify MB49 cell viability versus various 
concentrations of imatinib and imatinib concentrations in TEL:DPPC liposomes. (A) % Cell 
viability versus imatinib concentration (mM). The imatinib concentrations of imatinib 












 mM.  











 µM. The IC50 values were 
determined as: IC50 imatinib after 24 hr: 9.68x10
-2
 mM; IC50 of imatinib after 48hr: 3.12x10
-2
 
mM; and IC50 of TEL: DPPC liposome after 24 hr: 3.67x10
-1
 µM, IC50 of TEL: DPPC 













5.4.5 CAM Assay 
Daily microscopic measurements of parallel series of experiments from day 10 to day 18 were 
undertaken on MB49 cell implants onto CAM, in a total of 39 eggs. From day 13 to the last 









 mM, P: PBS Solution as a negative control) as well as 
suspensions of imatinib encapsulated TEL:DPPC liposomes (with the imatinib concentrations 






 μM, TO: Blank TEL:DPPC 
liposomes without imatinib content, TP:PBS Solution as a negative control) with the volume 
of 10 μl were topically applied to the implants.  
The anti-angiogenic responses to free imatinib and imatinib encapsulated TEL:DPPC 
liposomes in the time-course were monitored from day 13 until day 18.  
The implants were treated with various imatinib concentrations of the imatinib encapsulated 
liposome and free imatinib solution as well as blank liposomes and PBS. Both free imatinib 
and imatinib encapsulated liposomal treatments resulted in significant responses to the  
anti-angiogenic agent, with the decrease of the number of allantoic vessels proportionally to 
the concentration of the agent (Figure 4, 5, 6 and 7). The anti-angiogenic responses were 
illustrated with ―vessel total diameter/ tumor circumference‖ and ―vessel total diameter/vessel 
amount‖ versus treatment day, to provide a distinctive aspect to the anti-angiogenic effect on 
vessel deformation independently from the implant size. The illustration of the data in the 
form of ―vessel total diameter/tumor circumference‖ serves this cause. Also the ―vessel total 
diameter/vessel amount‖ versus treatment day provides a perspective on the anti-angiogenic 
effect on the blood vessels. On the 5
th
 day of treatment the highest concentration of the 







recognized. Indeed, with PBS topical application on to the implant on CAM (Figure 3), no 
anti-angiogenic effect was exerted. Beside implant surface area numerous allantoic vessels 
developed in a spoked-wheel pattern towards the implant. Supplementary Table 1 and 2 
provide the quantification of the anti-angiogenic response performed from day 13 to day 18 
with standard error of the mean of all triplicates. The results shown in Figure 4, 5, 6 and 7 
confirmed the morphological observations. When highest concentration of imatinib solution 
(A) was applied topically on the implant, vessel total diameter/tumor circumference ratio and 
vessel total diameter/vessel amount ratio were significantly decreased in comparison to the 
control implants. It was shown that the anti-angiogenic effect was strictly dependent on the 
concentration of the imatinib solution. On the other hand, during the liposomal treatment this 
concentration difference showed no significant effect. Also we observed a relatively late  
anti-angiogenesis response to the liposomal treatment compared to free imatinib solution. 
Moreover blank liposomes applied to the implants indicated no significant difference in 





















Figure 3. Time-course of the macroscopic appereance of a CAM implant. The sponges 
absorbed with 30.000 MB49 cells were implanted on day 10 (a, d, g). On day 13 before first 
topical treatments, vascular reaction was detected (b, e, h). On day 18 before the removal of 
implants the tumor and vessel morphology were investigated (c, f, i). On all images, 
numerous allantoic vessel were oriented towards the implant in a spoked-wheel pattern. In 
group A, the implants were treated with imatinib solution (1.0 mM) (b, c). Group TA was 
treated with imatinib encapsulated in TEL:DPPC liposomes (3.43 µM) (e, f). PBS: negative 









Figure 4. Vessel total diameter (µm) /Tumor circumference (µm), after the treatment with 









 mM, P: PBS solution as negative control). P < 0.05 for A, B, C, D 















Figure 5. Vessel total diameter (µm) /Vessel amount, after the treatment with imatinib 









 mM, P: PBS solution as negative control). P < 0.05 for A, B, C, D versus PBS 



















Figure 6. Vessel total diameter (µm) /Vessel amount, after the treatment with imatinib 







 µM TO: TO: Blank TEL:DPPC 
liposomes without imatinib content, TP:PBS solution as negative control). P < 0.001 for TA, 
TB, TC, TD versus PBS treatment, P < 0.05 for TE versus PBS treatment, P < 0.7 for TO 















Figure 7. Vessel total diameter (µm) /Vessel amount, after the treatment with imatinib 







 µM, TO: Blank TEL:DPPC liposomes 
without imatinib content, TP:PBS solution as a negative control). P < 0.001 for TA, TB, TC, 
TD versus PBS treatment, P < 0.05 for TA, TB, TC, TD versus PBS treatment, P < 0.6 for TE 
versus PBS treatment, P < 0.8 for TO versus PBS treatment. 
 
5.4.6 Western Blot 
 
The analysis of the anti-angiogenesis effect of imatinib encapsulated in TEL:DPPC liposomes 
on the implants on CAM was also carried out via Western Blot. In Western Blot 
measurements, proteins were prepared from the CAM implants and loaded onto the gel (20 µg 
for total ERK 1/2 and 30 µg for p-ERK 1/2). We took MB49 cell lysate and PBS treated 
implants from the CAM as negative controls. Western Blot results using both ERK 1/2 and  







and other treated implant samples removed from the CAM. Our results suggest that the 
highest inhibition was achieved with the treatment of TA group (Figure 8 and 9). Although 
the imatinib concentration applied to TA group was much lower than imatinib solution 
applied to (A) group.  The TEL:DPPC blank liposome (TO) showed no significant difference 
to the control group. From the samples we have tested, only TA showed a significant 





Figure 8. The total ERK 1/2 and phosphorilation of ERK 1/2 were determined by Western 
Blot analysis.  For total ERK 1/2, 20 µg protein/lane, for phosphorilation ERK 1/2, 30 µg 
protein/lane were used. MB: MB49 cell lysate. TA, TD: implant groups removed from the 
CAM, treated with TEL:DPPC liposomes, entrapped imatinib concentrations: TA:3.43, 
TD:1.14x10
-1
 µM. A, D: implant groups removed from the CAM, treated with free imatinib 
solutions, concentrations A:1.0, D:3.30x10
-2



























Figure 9. Signal Intensity of pERK 1/2 Total ERK 1/2. P values were calculated versus P 
(with PBS treatment) TA: p < 0.01, TD: p < 0.5, TO: p < 0.7, IA: p < 0.2, ID: p < 0.7.  



















5.5 Discussion and Conclusion 
In cancer therapy the use of chemotherapeutics is limited due to common damaging side 
effects. Hence, drug delivery systems have gained importance for lowering the daily doses 
and preventing side effects. However, there are several drawbacks that restrain the use of 
conventional liposomal carriers (42). Thus we employed TEL liposomes incorporated with a 
tyrosine kinase inhibitor. TEL liposomes were characterized by mean diameter, PDI and 
morphology. The mean size diameters of the liposomes were limited by extrusion through 
polycarbonate membrane filters; nevertheless, it was observed that imatinib encapsulated 
liposomes yielded larger than blank liposomes. Beni et al. has reported aggregation between 
DPPC liposomes due to molecular interaction of imatinib a DPPC liposomes (32). Although 
we have tailored the liposomes with 7:3 molar ratio of TEL:DPPC lipids, we observed 
smoothly shaped particles with a low ratio of aggregation in AFM images. This might be 
caused by a relatively high proportion of stable TELs in the liposome formulation. The TELs 
that we have employed in this study were extracted from biomass. As they were not purified, 
all cell components dissolved in CHCl3:MeOH (2:1, v/v) were present during the liposome 
preparations. During the experiment, we have filtered liposome suspensions through 0.45 mm 
filters. It was assumed that imatinib encapsulated liposomes may have grown larger and 
remained on the filter and could not flow through. This could provide an explanation to the 
decrease of the final concentration of imatinib encapsulated within TEL liposomes. Despite 
the relatively low final imatinib concentration, we observed effective anti-angiogenesis and 
anti-tumor effects during WST-1 and CAM assays.  
We monitored the anti-angiogenic effect of imatinib and imatinib encapsulated within 







a well-defined assay to provide a large perspective on blood vessels through angiogenic and 
anti-angiogenic responses. In this study it was demonstrated that MB49 cells induced 
vasoproliferation on CAM until treatment. After the first day of topical application of imatinib 
solution and imatinib encapsulated TEL:DPPC liposomes on the implants, this 
vasoproliferative effect showed significant decrease in comparison to the control treatment 
(PBS). Imatinib is a protein tyrosine kinase inhibitor, which has been defined to have a 
suppressive effect on Bcr-Abl, c-kit and platelet-derived growth factor receptor (PDGFR) 
(43). PDGFR is also known to be over-expressed during several vasculoproliferative diseases 
(44). Kim et al. reported that imatinib has an anti-angiogenesis effect due to targeting 
PDGF/PDGFR-signalling pathway beside in addition to an anti-tumor effect (45). A few years 
ago also anti-angiogenic effects of imatinib were reported by Kim et al. and Kvasnicka et al. 
(20, 45). Therefore in the current study we focused on imatinib mediated angiogenic 
suppression. It was reported that imatinib reduces the Bcr-Abl mediated secretion on VEGF 
(46).  In the literature there is a lack of data concerning the anti-angiogenesis effect of 
imatinib encapsulated TEL. Hence, we have examined free imatinib and imatinib 
encapsulated liposomes to provide a clear perspective of their effects on CAM micro-vessels. 
However, it was relatively difficult to distinguish the total anti-angiogenesis effect of free 
imatinib and encapsulated imatinib on the CAM assay. Highest concentration of imatinib (A) 
has a similar effect on anti-angiogenesis as the imatinib encapsulated liposomes (TA). On the 
other hand, lower concentration of encapsulated imatinib in TEL:DPPC liposomes (TE) 
exhibits no significant difference to higher concentration of liposomal encapsulated imatinib 
(TA). This indicates that with the encapsulated drug, a much lower concentration is sufficient 
to provide a similar anti-angiogenic effect. 
Before in ovo applications, we determined the effect of free imatinib and imatinib 







imatinib concentration of for free imatinib and liposomes, after 24 hours and 48 hours, a 
significant change was observed in comparison to control group on MB49 cells. It was also 
determined that the imatinib encapsulated liposomes -although having much lower 
concentration of imatinib- provided a similar effect on cell viability as the free imatinib itself. 
The maximum effect of free imatinib on the WST-1 assay was reached after 48 hours  
(Figure 2A). In contrast, imatinib encapsulated liposomes already reached maximum 
efficiency after 24 hours (Figure 2B). The blank TEL:DPPC liposomes might have caused an 
impact on cell viability as well. It was found that after 24 hours the IC50 of blank TEL:DPPC 
liposomes was 6.6x10
-2
 mM; this value was almost stable after 48 hours: 0.085 mM (data not 
shown). This characteristic could support imatinib function and therefore be a reason for 
better inhibition despite much lower imatinib concentration encapsulated in liposomes. These 
results were also supported by Western blot analysis (Figure 9). 
The cell proliferation on the CAM occurred diversely because of different circumstances 
during the cell growth process on the CAM due to the vascularisation and the distance to the 
vascular dense regions. Due to the nature of the procedure, during the removal of the implant 
from the CAM, connected egg tissue, such as membrane, blood vessels, blood, chorioallantoic 
fluid were removed together with the implant and involved in the Western Blot assay. Hence 
the assay always included some variable amount of quantified kinase from untreated tissue, 
resulting in a larger error value. Nevertheless, the Western blot results support the findings 
from the CAM assay. It is known that the ERK 1/2 pathway leads to the expression of VEGF; 
it is activated by multiple extracellular stimuli, including growth factors and it is a 
downstream target of Bcr-Abl (47). The treatment with imatinib encapsulated TEL:DPPC 
liposomes at the highest concentration of imatinib (TA) was found to result in a lowered 
concentration of pERK 1/2 (Figure 9) and therefore might have a significant effect on 







Our results show that the imatinib encapsulated TEL:DPPC liposomes, despite much lower 
imatinib content than used with free imatinib,  elicited an anti-angiogenic response which was 
correlated to the inhibition of the tyrosine kinase signal transduction cascade. 
In conclusion, during the first five days after free imatinib treatment and imatinib 
encapsulated liposome treatment, a significant anti-angiogenesis response was detected. The 
suppression efficiency was concentration dependant. 
Considering applications in cancer therapy, very stable TEL liposomes with appropriate 
release properties may play an important role in minimizing side effects of potentially harmful 

















Supplementary Table 1. The Normalized Values of Vessels total diameter (µm)/Tumor 
Circumference (µm) and Normalized Values of Vessel Total Diameter (µm) /Vessel Amount with the 
treatment of various concentrations of free imatinib data were presented in the presence of  
mean ± S.E.M 
        
    
Normalized Values of 
Vessels total diameter (µm) 
/Tumor Circumference (µm) 
± S.EM.  
Normalized Values of 
Vessel Total Diameter 
(µm) /Vessel Amount                     
± S.E.M Formulation 
Treatment 
Day 
A 1 1.00 ± 0.00 1.00 ± 0.00 
 2 0.87 ± 0.05 0.97 ± 0.06 
 3 0.76 ± 0.08 0.92 ± 0.07 
 4 0.67 ± 0.09 0.88 ± 0.09 
 5 0.58 ± 0.08 0.82 ± 0.07 
        
B 1 1.00 ± 0.00 1.00 ± 0.00 
 2 0.91 ± 0.06 0.96 ± 0.05 
 3 0.83 ± 0.09 0.90 ± 0.01 
 4 0.78 ± 0.15 0.95 ± 0.04 
 5 0.70 ± 0.13 0.87 ± 0.02 
        
C 1 1.00 ± 0.00 1.00 ± 0.00 
 2 0.91 ± 0.16 1.05 ± 0.20 
 3 0.73 ± 0.12 0.95 ± 0.15 
 4 0.74 ± 0.17 0.99 ± 0.14 
 5 0.73 ± 0.16 0.99 ± 0.14 
        
D 1 1.00 ± 0.00 1.00 ± 0.00 
 2 1.04 ± 0.03 1.05 ± 0.08 
 3 0.94 ± 0.05 1.06 ± 0.09 
 4 0.84 ± 0.07 1.02 ± 0.07 
 5 0.80 ± 0.08 1.03 ± 0.09 
        
E 1 1.00 ± 0.00 1.00 ± 0.00 
 2 1.01 ± 0.09 0.99 ± 0.06 
 3 1.08 ± 0.12 1.01 ± 0.07 
 4 1.02 ± 0.18 1.02 ± 0.05 
 5 1.07 ± 0.14 1.07 ± 0.06 
        
P 1 1.00 ± 0.00 1.00 ± 0.00 
 2 1.12 ± 0.09 1.00 ± 0.01 
 3 1.33 ± 0.13 1.05 ± 0.01 
 4 1.26 ± 0.17 1.14 ± 0.09 
 5 1.41 ± 0.29 1.16 ± 0.10 








Supplementary Table 2. The Normalized Values of Vessels total diameter (µm)/Tumor 
Circumference (µm) and Normalized Values of Vessel Total Diameter (µm) /Vessel Amount with the 
treatment of various concentrations of imatinib encapsulated TEL:DPPC liposomes data were 
presented in the presence of mean ± S.E.M   
 
 
    Normalized Values of 
Vessels total diameter 
(µm) /Tumor 
Circumference (µm)         
± S.EM.  
Normalized Values of 
Vessel Total Diameter 
(µm) /Vessel Amount                     
± S.E.M Formulation 
Treatment 
Day 
TA 1 1.00 ± 0.00 1.00 ± 0.00 
 2 0.99 ± 0.14 1.15 ± 0.11 
 3 0.80 ± 0.06 1.10 ± 0.06 
 4 0.55 ± 0.01 0.92 ± 0.04 
 5 0.44 ± 0.08 0.79 ± 0.07 
        
TB 1 1.00 ± 0.00 1.00 ± 0.00 
 2 0.83 ± 0.03 1.16 ± 0.03 
 3 0.87 ± 0.05 1.10 ± 0.13 
 4 0.72 ± 0.09 0.87 ± 0.12 
 5 0.60 ± 0.05 0.82 ± 0.10 
        
TC 1 1.00 ± 0.00 1.00 ± 0.00 
 2 0.96 ± 0.05 1.04 ± 0.06 
 3 0.81 ± 0.08 1.03 ± 0.14 
 4 0.80 ± 0.07 0.95 ± 0.07 
 5 0.71 ± 0.06 0.84 ± 0.10 
        
TD 1 1.00 ± 0.00 1.00 ± 0.00 
 2 0.89 ± 0.07 0.97 ± 0.03 
 3 0.80 ± 0.05 0.97 ± 0.07 
 4 0.67 ± 0.08 0.92 ± 0.07 
 5 0.67 ± 0.13 0.93 ± 0.08 
        
TE 1 1.00 ± 0.00 1.00 ± 0.00 
 2 0.86 ± 0.12 0.96 ± 0.09 
 3 0.78 ± 0.07 0.95 ± 0.08 
 4 0.82 ± 0.15 0.97 ± 0.13 
 5 0.86 ± 0.16 0.94 ± 0.11 
        







 2 1.14 ± 0.12 1.13 ± 0.08 
 3 1.22 ± 0.21 1.20 ± 0.10 
 4 1.18 ± 0.20 1.20 ± 0.05 
 5 1.27 ± 0.22 1.25 ± 0.11 
        
TP 1 1.00 ± 0.00 1.00 ± 0.00 
 2 1.15 ± 0.02 1.03 ± 0.08 
 3 1.49 ± 0.13 1.21 ± 0.15 
 4 1.66 ± 0.20 1.26 ± 0.18 
 5 1.72 ± 0.20 1.27 ± 0.16 
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6.1  Summary 
Liposomes currently have a broad spectrum of medical applications, especially in diagnostics 
and therapy. Stability of the liposomal drug carriers is one of the most important limitations, 
which concerns fast elimination of vesicles in the human body. Therefore in this thesis, very 
stable tetraether lipid liposomes were prepared and characterized. The study consists of the 
investigation of stability properties of tetraether lipid liposomes, the lectin conjugation onto 
the liposomal membrane, tyrosine kinase inhibitor encapsulation and characterization of these 
liposomes. These investigations were structured in five chapters:  
 
Chapter 1 introduced the tetraether lipid liposomes, their extraction and preparation methods, 
stability properties and pharmaceutical applications. In this context, modification and 
application of the tetraether lipid liposomes as drug delivery systems were also discussed. 
This chapter focused on the application of liposomes in the field of cancer therapy as anti-
angiogenic drug carriers.  
 
Chapter 2 describes the tetraether lipid liposomes which were tailored with an archaeal lipid, 
Glycerol Dialkyl Nonitol Tetraether (GDNT), isolated from the thermoacidophilic archaeon 
Sulfolobus acidocaldarius. Investigations of thermal stability, stability during autoclavation 
and pH stability were carried out. Furthermore, morphological images were presented. In this 
chapter a special lipid was isolated and purified for the preparation of liposomal vesicles. 
Liposomes tailored with GDNT showed high stability in various pH and temperature 
conditions. The results showed that the GDNT liposomes are even stable after autoclavation. 








Chapter 3 describes stability properties of tetraether lipid liposomes under conditions 
simulating the pulmonary system and gastrointestinal tract. The tetraether lipids were isolated 
from the thermoacidophilic archaeon Thermoplasma acidophilum. In contrast to the liposome 
formulations presented in Chapter 2, these liposomes were prepared with total tetraether lipids 
instead of a specific type of tetraether lipid. In addition to studies of pH stress and stability 
during autoclavation, the stability properties of these liposomes were investigated in fetal calf 
serum and lung surfactant conditions. The TEL content of the liposomes provides extreme 
stability to the liposomes which is very promising for drug delivery and targeting systems. 
The results of this work are considered as a preliminary study to elucidate the optimal ratio of 
tetraether lipid and conventional lipid for the following studies. 
 
Chapter 4 deals with lectin-carbohydrate interactions. The model lectin Concanavalin A 
(ConA) extracted from the Jack-bean Canavalia ensiformis was used to modify tetraether 
lipid liposomes. ConA binds to sugar domains localized on inflamed tissues or tumors. The 
ConA modified TEL liposomes provide an effective targeting mechanism to the inflamed area 
or tumors. The polymeric form of the sugar mannose, ―mannan‖, was used for the surface 
modification of a bio-chip. This bio-chip simulated the carbohydrate residues on the cell 
surface. The binding properties of ConA- modified liposomes onto the mannan coated chip 
surface were investigated with Reflectometric Interference Spectroscopic (RIfS) 
measurements which were performed with a BIAffinity device and subsequently with Atomic 
Force Microscopy (AFM). These measurements provide full information about the binding 
characteristics of ConA onto the mannan surface. In this regard, ConA can be considered as a 
useful model for the investigation of specific biomarkers. In the future, ligand conjugated 








Chapter 5 presents an anti-angiogenic effect of a tyrosine kinase inhibitor entrapped in 
tetraether lipid liposomes to protect the drug and to decrease the adverse effects on the 
organism. The anti-angiogenic effect was determined by investigation of blood vessels on a 
chorioallantoic membrane (CAM) model, especially because of its dense capillary network 
and eligibility of continuous screening of the implant. Besides in ovo investigations, anti-
angiogenic effects of the tyrosine kinase inhibitor ―imatinib‖ entrapped tetraether liposomes 
were elucidated with cell viability and Western blot assays. According to the comparative 
results of application between imatinib solution and imatinib encapsulated tetraether lipid 
liposomes, tetraether lipid liposomes were considered to be promising carriers for tyrosine 
kinase inhibitors due to the high anti-angiogenesis efficiency with much lower drug 
concentration. This approach yields to decrease the undesirable side effects of the drug and 




















Within the scope of this thesis, investigations of tetraether lipid (TEL) liposomes were 
performed in two sections, which were namely liposomal targeting and liposomal drug 
delivery. Since both aspects were examined separately, an essential future perspective of this 
study is the investigation of a combined application of those two systems to finally provide a 
tetraether lipid liposomal drug carrier with a targeting mechanism.  
To achieve an effective drug delivery and targeting model, the stability of ligand conjugated 
liposomes and tyrosine kinase inhibitor entrapped TEL liposomes obviously needs to be 
explored under different thermal, pH, fetal calf serum, lung surfactant and other conditions 
concerning the application region.  
 
In Chapter 4, a ligand modification of tetraether lipid liposomes was tailored with a model 
ligand Concanavalin A, to investigate lectin-carbohydrate interactions of the tetraether lipid 
liposomes to the carbohydrate surface. This interaction is an unspecific interaction.  For an 
effective targeting model, more specific ligands need to be investigated with Reflectometric 
Interference Spectroscopy. 
 
In Chapter 5, the CAM model, which is known as an in ovo method, was investigated. A 
posterior step to the in ovo experiments is the in vivo study of ligand conjugated TEL 
liposomes with an encapsulated drug in order to evaluate the systemic effect of a tyrosine 
kinase inhibitor entrapped in ligand conjugated /nonconjugated tetraether lipid liposomes to a 










Liposomen bieten ein breites Spektrum an medizinischen Anwendungsmöglichkeiten, 
besonders in der Diagnostik und der Therapie. Die Stabilität der Liposomen als 
Wirkstoffträger stellt dabei eine der größten Einschränkungen in der Anwendung dar, da die 
Gefahr eines schnellen Abbaus der Vesikel im menschlichen Körper besteht. Daher wurden 
im Rahmen dieser Arbeit hochstabile Tetraetherlipid-Liposomen (TEL-Liposomen) 
hergestellt und charakterisiert. Die vorliegende Arbeit umfasst die Untersuchung der Stabilität 
von Tetraetherlipid-Liposomen, die Lectinbindung dieser Liposomen und schließlich 
Liposomen als Träger eines Anti-Angiogenese-Wirkstoffes. Diese Untersuchungen sind in 
fünf Kapiteln strukturiert. 
 
Kapitel 1 gibt eine Einführung in Tetraetherlipid-Liposomen, stellt Methoden zur Extraktion 
und Reinigung vor und beschreibt pharmazeutische Anwendungsmöglichkeiten. Darüber 
hinaus werden Modifikationen von TEL-Liposomen und deren Nutzung zum 
Wirkstofftransport diskutiert. Der Fokus dieses Kapitels liegt auf dem Einsatz von Liposomen 
als Antiangiogenese-Wirkstofftransporter in der Krebstherapie.  
 
Kapitel 2 charakterisiert Tetraetherlipid-Liposomen, die aus einem Archea-Lipid, Glycerol-
Dialkyl-Nonitol-Tetraether (GDNT), hergestellt wurden, das aus dem thermoacidophilen 
Archaeon Sulfolobus acidocaldarius isoliert wurde. Es wurden Untersuchungen zur 
Thermostabilität, Stabilität während des Autoklavierens und pH-Stabilität durchgeführt. 







wurde ein spezifisches Lipid isoliert und gereinigt, um Liposomen herzustellen. Liposomen 
aus GDNT weisen eine hohe Stabilität in unterschiedlichen pH- und Temperaturbedingungen 
auf. Es konnte gezeigt werden, dass GDNT-Liposomen sogar nach dem Autoklavieren stabil 
bleiben. Kapitel 2 liegt in Form eines Methodenprotokolls vor. 
 
Kapitel 3 beschreibt die Stabilitätseigenschaften von Tetraetherlipid-Liposomen unter 
Bedingungen, die die physiologischen Gegebenheiten im Atmungssystem und Magen-Darm-
Trakt simulieren. Hierzu wurden Tetraether-Lipide aus dem thermoacidophilen Archaeon 
Thermoplasma acidophilum isoliert. Im Gegensatz zu den in Kapitel 2 vorgestellten 
Liposomzusammensetzungen wurden hier Liposomen aus dem Gesamtumfang der isolierten 
Tetraether-Lipide anstatt aus einer bestimmten Fraktion hergestellt. Zusätzlich zu 
Untersuchungen der Stabilität unter pH-Stress und Autoklavierungs-Bedingungen wurden die 
Liposomen in fetalem Kälberserum und Lungen-Surfactant untersucht. Der TEL-Anteil in den 
Liposomen verhilft ihnen dabei zu hoher Stabilität. Dies ist vielversprechend für einen 
späteren Einsatz im zielgerichteten Wirkstofftransport. Diese Untersuchungen können als 
Vorversuche zur Ermittlung der optimalen Lipidzusammensetzung von Liposomen angesehen 
werden, die in den weiterführenden Studien genutzt werden sollen. 
 
Kapitel 4 beschäftigt sich mit Lectin-Kohlenhydrat-Interaktionen. Das Lektin Concavalin A 
(ConA), gewonnen aus der Jackbohne Canavalia ensiformis, wurde hier zur Modifikation von 
Tetraetherlipid-Liposomen eingesetzt. ConA bindet an Zuckerdomänen, wie sie in 
entzündetem Gewebe oder Tumoren vorkommen. Die ConA – modifizierten TEL-Liposomen 







Polymerform des Zuckers Mannose, „Mannan―, wurde zur Beschichtung eines Bio-Chips 
genutzt, so dass Kohlenhydratreste auf einer Zelloberfläche simuliert werden konnten. Die 
Affinität der ConA – modifizierten Liposomen zum mannanbeschichteten Biochip wurde 
mittels Reflektrometrischer Interferenzspektroskopie untersucht, die mit einem BIAffinity-
Gerät durchgeführt wurde, und weiterhin mittels Rasterkraftmikroskopie. Diese Messungen 
erlauben die vollständige Charakterisierung der Bindung von ConA an die Mannanoberfläche. 
In diesem Zusammenhang kann die ConA-Modifikation der TEL-Liposomen als 
Modellversuch für die Untersuchung spezifischer Biomarker betrachtet werden. Künftig 
könnten TEL-Liposomen als wirksame zielgerichtete Wirkstoffträger zum Einsatz kommen. 
 
Kapitel 5 schildert den Antiangiogenese-Effekt des Tyrosinkinaseinhibitos „imatinib―, der in 
TEL-Liposomen eingschlossen wurde, um den Wirkstoff zu schützen und Nebenwirkungen 
auf den Organismus zu minimieren. Der Antiangiogenese-Effekt wurde an Blutgefäßen in 
einem CAM-Modell (Chorioallantoische Membran im Hühnerei) untersucht, insbesondere 
aufgrund des dichten Kapillarnetzwerks und der Eignung für kontinuierliche Beobachtung des 
Implantats. Neben den in-ovo-Untersuchungen wurde der Antiangiogenese-Effekt der 
imatinib-beladenen TEL-Liposomen mittels Zellviabilität- und Western-Blot-Analysen 
charakterisiert. Aufgrund der gewonnen Erkenntnisse im direkten Vergleich von imatinib-
geladenen TEL-Liposomen mit imatinib-Lösung konnten die TEL-Liposomen als 
vielversprechende Vektoren für Tyrosinkinaseinhibitoren dargestellt werden, da sie eine hohe 
Antiangiogeneseeffizienz mit einer niedrigeren Wirkstoffkonzentration erreichen. Dieser 
Ansatz soll helfen, unerwünsche Nebeneffekte des verwendeten Wirkstoffes zu minimieren 










Im Rahmen dieser Arbeit wurden Tetraetherlipid-Liposomen unter zwei verschiedenen 
Aspekten untersucht: Liposomen-Targeting und Wirkstofftransport durch Liposomen. Da 
bisher beide Aspekte getrennt untersucht wurden, ist ein wichtiger nächster Schritt die 
Kombination beider Systeme, um schließlich ein Wirkstofftransportsytem mit 
Targetingfunktion auf der Basis von Tetraetherlipid-Liposomen etablieren zu können.  
Bisher wurde die Stabilität von unmodifizierten TEL-Liposomen ohne Beladung untersucht – 
um ein erfolgreiches Wirkstofftransportsystem zu etablieren, müssen im weiteren Verlauf die 
ligandgebundenen Liposomen sowie Tyrosinkinaseinhibitor-beladene Liposomen unter 
Stressbedingungen wie hohe Temperaturen, verschiedene pH-Werte, Inkubation in fetalem 
Kälberserum und Lungen-Surfactant sowie anderer Bedingungen, die am gewünschten 
Einsatzort vorherrschen, untersucht werden.  
In Kapitel 4 wurden mit dem Liganden Concavalin A gebundene TEL-Liposomen hergestellt, 
um Lectin-Kohlenhydrat-Interaktionen der modifizieren TEL-Liposomen mit einer 
kohlenhydratbeschichteten Oberfläche zu Untersuchen. Bei dieser Art der Interaktion handelt 
es sich um eine unspezifische. Für ein effektives Targeting sollten nun mittels 
Reflektrometrischer Interferenzspektroskopie Liganden untersucht werden, die eine 
spezifischere Interaktion ermöglichen. 
Kapitel 5 beschreibt das CAM-Modell als eine Methode des in-ovo-Screenings. Ein 
notwendiger Folgeschritt zu den in-ovo-Beobachtungen beinhaltet in-vivo-Experimente mit 







des systemischen Effekts des Einsatzes Tyrosinkinaseinhibitor-beladener ligandgebundener 



























7.1  Abbreviations 
 
AFM  Atomic Force Microscopy 
abl  Abelson murine leukemia gene 
bcr  Breakpoint cluster region gene 
bFGF  Basic Fibroblast Growth Factor 
BIA  Biomolecular Interaction Analysis 
BM  Bone Marrow 
CAM  Chorioallantoic Membrane 
CF  5(6)-Carboxyfluorescein 
CML  Chronic Myeloid Leukemia 
ConA  Concanavalin A 
DLS   Dynamic Light Scattering 
DPPC  L-Alpha-dipalmitoyl phosphatidylcholine 
EDTA  Ethylenediaminetetraacetic acid 
EE  Encapsulation Efficiency 
ELISA  Enzyme-Linked Immunosorbent Assay 
ERK  Extracellular-Signal-Regulated Kinase 
FCS  Fetal Calf Serum 
HEPES 2-[4-(2-Hydroxyethyl)-1-piperazinyl]ethanesulfonic Acid 
GDNT  Glycerol Dialkyl Nonitol Tetraether  
GIST  Gastrointestinal Stromal Tumor 
IC50   Half-Inhibitory Concentration 







LDA  Laser Doppler Anemometry  
MAPK Mitogen-Activated Protein Kinase  
PBS   Phosphate Buffered Saline 
PCS  Photon Correlation Spectroscopy 
PDGF  Platelet-Derived Growth Factor 
PDGFR Platelet-Derived Growth Factor Receptor 
PDI   Polydispersity Index 
PECAM-1 Platelet Endothelial Cell Adhesion Molecule-1 
PEG  Poly(ethylene Glycol) 
Ph  Phospholipon 100H 
RES  Reticulo-Endothelial System 
RIfS  Reflectometric Interference Spectroscopy 
RT  Room Temperature 
SD  Standard Deviation of the Mean 
SEM  Standard Error of the Mean 
SPF  Specific Pathogen Free 
TEL  Tetraether Lipid  
TGF-β  Transforming Growth Factor Beta 
VEGF  Vascular Endothelial Growth Factor  
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